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ABSTRACT 
This study examined the efficacy and feasibility of a brief telephone-delivered CBT-I 
(TeleCBT-I) intervention in cancer patients compared to a control group. The study used a 
randomized controlled trial design. The TeleCBT-I program consisted of a brief four-week CBT-
I program adapted for cancer patients. Patients completed assessment measures at pre-treatment, 
post-treatment and one-month follow-up. Out of 184 patients screened, 39 were randomly 
assigned, and 35 (TeleCBT-I, n = 19; Control, n = 16) completed pre- and post-treatment 
measures and were included in the analyses. Compared to control group, the TeleCBT-I group 
reported decreased insomnia severity symptoms (p < .014), improved sleep quality (p < .023), 
and reduced dysfunctional beliefs about sleep (p = .039) at post-treatment with sustained 
treatment effects at one-month follow-up. Sleep measures yielded large effect sizes (Hedges’ g, 
0.84-2.7). Although the TeleCBT-I group indicated improvements in fatigue, general 
functioning, physical well-being, functional well-being, and physical quality of life, effects at 
follow-up were observed only for fatigue, functional well-being and physical quality of life. No 
effects were found on depression at any of the time points. In terms of feasibility, TeleCBT-I 
demonstrated high adherence, high homework completion and high overall satisfaction. These 
results advance the empirical evidence of CBT-I in cancer patients and support the use of 
telephone-delivered CBT-I to widely disseminate and implement among patients with cancer.  
Key words: CBT-I, Insomnia, Cancer, Telephone, Telehealth  
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CHAPTER ONE: INTRODUCTION  
Insomnia is a common and debilitating condition that can affect cancer patients at any 
time in the cancer continuum, from pre-diagnosis through long-term cancer survivorship. It is 
estimated that up to 80% of cancer patients experience sleep disturbances, while up to 30% to 
60% suffer from insomnia (Savard, Ivers, Savard, & Morin, 2015, 2016; Sharma et al., 2012). If 
left untreated, insomnia is likely to become chronic, affecting the healing process and tumor 
progression in cancer populations (Cash et al., 2015). Insomnia has been associated with a 
number of negative physical and psychological consequences including: fatigue, pain, 
depression, anxiety, diabetes, cardiovascular disease, poor quality of life, and even early 
mortality (Palesh et al., 2017; Savard, Villa, Ivers, Simard, & Morin, 2009).  
Considering that insomnia symptoms in cancer patients are often severe enough to 
warrant treatment, the American College of Physicians (ACP, Qaseem et al., 2016) guidelines 
recommend the screening and assessment of sleep complaints and treatment of insomnia during 
routine cancer care. Furthermore, the ACP asserted that all adult patients with cancer and 
comorbid insomnia symptoms receive cognitive behavioral therapy for insomnia (CBT-I) as the 
first line of treatment. Mounting evidence has demonstrated that CBT-I is effective to treat 
severe insomnia in adult populations, including cancer patients (Garland et al., 2014; Johnson et 
al., 2016; Zachariae, Lyby, Ritterband, & O’Toole, 2016). Emerging evidence suggests that 
CBT-I may also be beneficial in targeting other psychological outcomes in cancer patients, such 
as depression, anxiety and fatigue, as well as, quality of life (Dirksen & Epstein, 2008; Johnson 
et al., 2016). 
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Despite its high prevalence and negative impact in health, tumor progression, daily 
functioning, quality of life, and survival, insomnia is often under-recognized, under-diagnosed 
and under-treated in oncology settings (Geiger-Brown et al., 2015; Innominato et al., 2009; 
Johnson et al., 2016). Research has highlighted a number of challenges for cancer patients to 
receive CBT-I in a timely fashion, including lack of awareness of CBT-I, low clinician priority 
and referrals, limited trained providers, commute to treatment centers, and high cost and duration 
CBT-I (Manber & Simpson, 2016; Siefert, Hong, Valcarce, & Berry, 2014; Sivertsen, Vedaa, & 
Nordgreen, 2013). Another important challenge is that when treatment is offered, it generally 
consists of sleep medication (Sandlund, Hetta, Nilsson, Ekstedt, & Westman, 2017; Siefert et al., 
2014), increasing the number of medications and side effects during cancer treatment.   
Telehealth modalities have emerged as viable options to reduce barriers in care and 
improve clinical health outcomes (Perle & Nierenberg, 2013). The number of telehealth 
technologies and delivery formats is growing from live interactive video that allows providers to 
provide remote intensive home care to mobile applications that patients use to access health 
information and manage their health (Holmqvist, Vincent, & Walsh, 2014; Perle & Nierenberg, 
2013). Given the empirical evidence demonstrating that CBT-I can help people sleep better, 
there is a growing interest in its widespread dissemination and implementation with all 
populations. Telehealth modalities can circumvent the challenges in disseminating CBT-I 
without reducing its effectiveness. Indeed, promising research indicates that both internet-based 
and telephone-delivered CBT-I programs are as effective as face-to-face individual and group 
modalities in adult samples (Arnedt et al., 2013; Ritterband et al., 2017; Zachariae et al., 2016).  
3 
 
Further research is needed to determine whether insomnia can be treated by delivering 
CBT-I through telehealth. Considering the huge potential of telehealth in increasing access, 
quality and efficiency in care (Chaet, Clearfield, Sabin, & Skimming, 2017), it is imperative to 
test CBT-I with different telehealth formats to improve patient health, particularly for individuals 
with chronic and debilitating conditions, such as cancer. Telehealth technologies may reduce 
barriers to disseminate and implement CBT-I in oncology settings. For example, patients can 
have access to CBT-I information and psychotherapy from the convenience of their home or 
work office, eliminating practical barriers, such as transportation issues, child care, as well as 
reduce overall cost and time invested in accessing care (Brenes, Ingram, & Danhauer, 2011; 
Chaet et al., 2017).  
Although there is abundant interest in pursuing a widespread dissemination of CBT-I 
utilizing telehealth technologies, there is a lag in research with cancer patients. Telehealth 
research with CBT-I have largely focused on internet-based and mobile applications, despite 
telephone communication still being the most convenient, cost-effective, and ever-present form 
of communication in the United States and worldwide (Brenes et al., 2011).  
To date, no research has examined CBT-I delivered through telephone communication 
with cancer patients. The present study adapted and tested a 4-week CBT-I program delivered 
via telephone to cancer patients. The main objectives were to test the efficacy and feasibility of a 
brief telephone-delivered CBT-I (TeleCBT-I) program in cancer patients. In this randomized 
controlled study, the effects of TeleCBT-I were compared to a treatment-as-usual control group. 
TeleCBT-I treatment gains over time were examined at one-month follow-up. The feasibility of 
telephone-delivered CBT-I in cancer patients was evaluated over the course of four weeks.  
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CHAPTER TWO: LITERATURE REVIEW 
Insomnia 
Insomnia is characterized by subjective complaints about difficulty initiating sleep, 
difficulty maintaining sleep, waking up too early in the morning or experiencing non-restorative 
or poor quality of sleep (Qaseem et al., 2016; Roth, 2007).  As per the International Guidelines 
of Sleep Disorders (Thorpy, 2017), both reduced sleep time and impaired daytime functioning 
are important aspects in the diagnosis of insomnia disorder. The clinical diagnosis of chronic 
insomnia disorder according to the American Psychiatric Association’s Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5) and the International Classification of Sleep 
Disorders, Third Edition, specify that symptoms cannot be associated with another sleep or 
medical disorder, must cause clinically significant functional impairment and be present at least 
three days in a week and for at least three months (American Psychiatric Association, 2013; 
Thorpy, 2017). 
The prevalence of insomnia is higher among women than men and tends to increase as 
people age with a sharp spike among adults aged 55-64 years old as observed in the National 
Health Interview Survey from 2002-2012 (Ford, Cunningham, Giles, & Croft, 2015). The 
development and progress of insomnia seems to be determined by predisposing, precipitating, 
and perpetuating factors (Bastien, Morin, Ouellet, Blais, & Bouchard, 2004). Predisposing 
factors may include a person’s genetics, gender, age, family history, trait anxiety, and 
predisposition to rumination (Bush et al., 2016; Hammerschlag et al., 2017; Harvey, Gehrman, & 
Espie, 2014), while precipitating factors consist of psychological and physical dysfunctions and 
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environmental, family and work-related circumstances. In cancer patients precipitating factors 
may include diagnosis of cancer, severity of disease, cancer treatment, side effects of cancer 
treatment, menopausal symptoms including pain or fatigue, and medications (Bastien et al., 
2004; Savard et al., 2009). Perpetuating behavioral factors include long-term use of medications 
or use of inappropriate medications, and dysfunctional coping (i.e., inaccurate appraisal of sleep 
difficulties and quality) (Tremblay, Savard, & Ivers, 2009).  
The American Academy of Sleep Medicine and Sleep Research Society consensus 
recommends seven or more hours of sleep to promote optimal health in adults. Aside from 
increasing the number of hours of sleep, the goal of treatment for insomnia is to improve sleep 
quality, as well as, to reduce day time impairment caused by the disorder (Schutte-Rodin, Broch, 
Buysse, Dorsey, & Sateia, 2008). Treatment options for insomnia include psychological therapy, 
pharmacologic therapy, or a combination of both (Qaseem et al., 2016). Psychological therapy 
options include CBT-I, multicomponent behavioral therapy or brief behavioral therapy for 
insomnia, and other interventions such as stimulus control, relaxation strategies, and sleep 
restriction. Among these interventions, CBT-I is considered the gold standard treatment for 
insomnia as per clinical guidelines and practice parameters of the American Academy of Sleep 
Medicine and the American College of Physicians (Qaseem et al., 2016; Sateia, Buysse, Krystal, 
Neubauer, & Heald, 2017).  
Cognitive-Behavior Therapy for Insomnia (CBT-I) 
The evidence that CBT-I is an effective treatment for insomnia and produces enduring 
effects lasting beyond treatment has been established. CBT-I was designed to improve sleep 
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disturbance by addressing psychological and behavioral factors involved in the development and 
maintenance of insomnia (Morin et al., 2015; Siebern & Manber, 2011). CBT-I combines 
components of cognitive and behavioral therapies. Cognitive therapy addresses dysfunctional 
beliefs and thoughts about sleep, while behavioral therapy targets behaviors and habits that do 
not promote sleep and are not conducive to healthy sleep patterns (Morin, 2010). The major 
components in CBT-I include: cognitive restructuring (CR), stimulus control (SC), sleep 
restriction (SR), sleep hygiene (SH), and relaxation techniques (RT) to improve sleep outcomes 
(Siebern & Manber, 2011; Annemieke van Straten et al., 2018). CBT-I is often provided 
individually or in group formats and traditionally is delivered during the course of eight to 
twelve sessions (Manber & Simpson, 2016; Siebern & Manber, 2011). 
Accumulative evidence including randomized controlled trials, meta-analyses (Koffel, 
Koffel, & Gehrman, 2015; Sandlund et al., 2017; Trauer, Qian, Doyle, Rajaratnam, & 
Cunnington, 2015; Annemieke van Straten et al., 2018) and systematic reviews (Cunningham & 
Shapiro, 2018; Mitchell et al., 2014) established that CBT-I is an effective treatment for adults 
with chronic insomnia with clinically and statistically significant effect sizes. Indeed, a recent 
review and meta-analysis assessed the efficacy of face-to-face CBT-I on 20 randomized 
controlled trials and demonstrated that CBT-I at post-treatment improved sleep time by 7.61 (CI, 
-.51 to 15.74) minutes and sleep efficiency by 9.91% (CI, 8.09% to 11.73%) with sustained gains 
over time (Trauer et al., 2015).  
Furthermore, emerging evidence supports the use of CBT-I in adults with comorbid 
medical or psychiatric conditions (Geiger-Brown et al., 2015). Although the efficacy and 
effectiveness of CBT-I is well-established, CBT-I is under-utilized in medical settings. 
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Therefore, researchers have called attention to the need of facilitating the dissemination and 
implementation of CBT-I to all populations, including cancer patients who may experience 
additional barriers to care. Moreover, current trends in the literature suggest reducing the length 
of CBT-I and establishing evidence for other forms of delivery in order to reach a greater number 
of patients (Morin, 2010; Sandlund et al., 2017; Zhou, Partridge, & Recklitis, 2017). 
CBT-I for Cancer Patients 
Compared to pharmacological treatment, CBT-I has been associated with substantial and 
sustained clinical benefits among cancer patients (Heckler et al., 2016; Peoples et al., 2017). A 
recent systematic review of CBT-I with patients of different types of cancers reviewed 12 trials 
(4 controlled and 6 uncontrolled) and found that CBT-I was associated with statistically and 
clinically significant improvements in subjective sleep outcomes (Garland et al., 2014). 
Additionally, this review demonstrated that CBT-I had positive effects in mood, fatigue, and 
overall quality of life. CBT-I was also successfully delivered through a variety of treatment 
modalities (e.g., self-help, videoconferencing and individual and group therapy). Moreover, 
Garland et al., (2014) concluded that studies with homogeneous cancer groups did not have a 
treatment advantage over studies that included mixed groups of cancer patients, suggesting that 
treatment effects may be similar irrespective of cancer stage and tumor location. Nonetheless, 
most research has been conducted with breast cancer patients, highlighting the need to 
investigate the effect of CBT-I concurrent with a broad range of cancer diagnoses. For example, 
in a recent meta-analysis of randomized controlled trials of CBT-I in cancer patients, three of the 
eight studies evaluated included patients with mixed cancer diagnoses (Johnson et al., 2016) 
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CBT-I for Breast Cancer Patients (BCS) 
CBT-I is an efficacious treatment for people with comorbid breast cancer and insomnia. 
Using the main components of the CBT-I (i.e., SC, RT, SH, and CR), researchers have examined 
CBT-I delivered in individual, group and self-administered modalities with breast cancer 
patients. Studies included both uncontrolled and controlled trials. A multiple baseline single 
subject study evaluated CBT-I and fatigue management in women with breast cancer stages I-III 
(N =10). This study found that although sleep severity was significantly decreased at six-month 
follow-up, there was no significant decline in depression, anxiety, fatigue, or quality of life 
(Quesnel, Savard, Simard, Ivers, & Morin, 2003). Another study found that women with breast 
cancer stage I-III (N = 11) who participated in a self-administrated program of CBT-I reported 
significantly reduced insomnia severity, depression, and increased quality of life, but no 
significant reduction in anxiety and depression at three-month follow-up (Savard, Villa, Simard, 
Ivers, & Morin, 2011). These findings provide mixed evidence that CBT-I may have an effect on 
other psychological variables such as depression, anxiety, fatigue, and quality of life, and 
therefore more research is needed. 
Most controlled trials showed positive outcomes associated with CBT-I in BCS. Dirksen 
& Epstein (2008) tested the efficacy of a multicomponent CBT-I in BCS compared to a control 
group that received sleep education and information on sleep hygiene. The study included 72 
women who were at least three-month post-primary cancer treatment. Both groups sustained 
significant time effects for sleep onset latency, wake after sleep onset, time in bed, sleep 
efficiency and sleep quality after treatment. Although this study may have minimized the effect 
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of CBT-I over a psychoeducational sleep approach, it also indicates that low intensity sleep 
intervention may have a significant impact on BCS.  
Other controlled trials have demonstrated that CBT-I reduced insomnia severity, 
depression, anxiety, and fatigue, and increased quality of life on women with breast cancer 
stages I-III (Barsevick et al., 2010; Casault, Savard, Ivers, & Savard, 2015;  Mitchell, Gehrman, 
Perlis, & Umscheid, 2012; Savard et al., 2011). Similar treatment effects have been found even 
when CBT-I is delivered during chemotherapy treatment. Mitchell et al., (2009) examined the 
effects of individual CBT-I on a group of 219 women who were randomly assigned before 
chemotherapy treatment to CBT-I group or a health-eating control condition. Differences were 
found between groups in sleep quality and sleep efficiency at 30-days posttreatment, but only 
improved sleep quality was sustained at one-year follow-up. Together, these findings support 
that CBT-I is effective at improving insomnia symptoms in BCS. Additionally, these findings 
also highlight the need to investigate whether CBT-I is also helpful at targeting other 
psychological symptoms comorbid with insomnia and faced throughout the cancer treatment 
continuum.   
Telehealth 
Telehealth utilizes a broad range of electronic information and telecommunication 
technologies to provide long-distance clinical health care (Weinstein et al., 2014). Technologies 
include a wide range of options from low-cost applications such as telephone, video or home 
computers to more complex ones, such as telesurgery (Chaet et al., 2017; Porzsolt & Kaplan, 
2006). The terms telehealth and telemedicine are often used interchangeably even by leading 
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telehealth and telemedicine organizations (American Telemedicine Association, 2016). The main 
difference is in the range of services provided, as telemedicine concerns with the delivery of 
diagnostic and clinical services, while telehealth extends to a broader range of services including 
patient care, self-management, and education (American Telemedicine Association, 2016). 
Telehealth and CBT-I. 
Given that the effectiveness of CBT-I in cancer patients is well documented, the next 
scientific venture is to make CBT-I more accessible and cost-effective for all populations. 
Telehealth supports novel applications to delivering CBT-I to individuals who would not 
otherwise have access to treatment.  
Although limited, emerging research support the use of telehealth technologies to 
disseminate CBT-I. Growing evidence favors the use of internet-based applications of CBT-I. 
Several clinical trials demonstrated that web-based CBT-I delivered by an automated virtual 
therapist (Espie et al., 2008) or guided by a therapist (Blom et al., 2015; Kaldo et al., 2015; van 
Straten et al., 2014), as well as, self-help or self-administered interventions (Connelly, Gee, & 
Walsh, 2007; Lancee, van den Bout, van Straten, & Spoormaker, 2012; Ritterband et al., 2009; 
Ström, Pettersson, & Andersson, 2004). For example, a recent meta-analysis included eleven 
randomized controlled trials published from 2004 to 2015 and examined 1,460 participants, 
documenting that CBT-I delivered via telehealth improved insomnia symptoms at post-treatment 
with effect sizes (Hedges’ g) for insomnia severity of 1.09, 0.58 for sleep efficiency, 0.49 for 
sleep quality and .021 for number of nocturnal awakenings (Zachariae et al., 2016). Treatment 
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outcomes were comparable with those found in face-to-face CBT-I interventions and were 
sustained at one-month to twelve-month follow-up.  
Research on telehealth and CBT-I is fairly new and even more so with cancer patients. 
Out of the eleven studies included in a recent meta-analysis, only one was conducted with cancer 
patients (Zachariae et al., 2016). The sample included 28 cancer patients randomized to either 
internet-based CBT-I or waitlist control group (Ritterband et al., 2012). Findings indicated that 
participants in the internet-based CBT-I group showed improvements in insomnia symptoms at 
post-treatment compared to control group. Although encouraging, this evidence highlights the 
need to further investigate the efficacy of CBT-I delivered via telehealth modalities to cancer 
patients.  
In this review of the literature only six empirical studies of CBT-I using some form of 
telehealth with cancer patient were found (Epstein & Dirksen, 2007; Ritterband et al., 2012;  
Savard, Ivers, Savard, & Morin, 2014; Savard et al., 2016, 2011; Zhou, Vrooman, Manley, 
Crabtree, & Recklitis, 2017). Table 1 presents a summary of the six studies. These studies 
examined a wide range of telehealth modalities, including: internet-based, self-administered 
animated videos, video conference, and a combination of group therapy with individual 
telephone calls, providing preliminary evidence for the use of telehealth to deliver CBT-I in 
cancer populations. Although promising, more research is needed to determine which telehealth 
format is more conducive to disseminate CBT-I without affecting its effectiveness in treating 
insomnia in cancer patients. Furthermore, although one study included telephone calls (Dirksen 
& Epstein, 2008), the telephone calls served as supplement to the actual group therapy and thus it 
does not constitute a true use of telehealth in providing CBT-I. These findings also highlight the 
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need to investigate whether telephone-delivered CBT-I is efficacious and feasible in cancer 
populations.  
Telephone-delivered CBT-I  
Telehealth application such as individual telephone calls is far more cost-effective and 
accessible to deliver than traditional face-to-face interventions and even more so than other 
forms of telehealth, such as video-conferencing and internet-based therapy (Brenes et al., 2011). 
Two studies have examined the use of telephone-delivered CBT-I. Bastien et al., (2004) 
compared face-to-face individual therapy, face-to-face group therapy and telephone consultations 
with 45 adults with insomnia. This study found that CBT-I was effective in reducing insomnia 
symptoms across treatment modalities and at six-month follow-up. Another study compared 
CBT-I delivered by telephone (n = 15) to passive control group (n = 15). The control group 
received an informational brochure (Arnedt et al., 2013). Both groups reported significant effect 
in all sleep measures. It is possible that the content of the brochure included some aspects of 
CBT-I, thus making it more therapeutic than intended. These findings suggest that some aspects 
of CBT-I could be beneficial as a stand-along intervention and potentially that a full dose of 
CBT-I is not warranted for all populations. Future research should explore the effect of 
telephone-delivered CBT-I compared to a control group, particularly to non-treatment control or 
wait-list control in order to discern whether changes between groups are greater for CBT-I 
delivered by telephone than a pure non-treatment group.  
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Telephone-delivered Interventions for Cancer Patients   
Telehealth in the form of individual telephone calls or telephone consultations has been 
associated with positive outcomes and high levels of satisfaction among cancer patients receiving 
cancer genetic counseling (Zilliacus et al., 2010). Another study documented the use of a nurse-
led telephone-based intervention to support cancer patients receiving oral chemotherapy 
(Barsevick et al., 2010). Although this intervention was not randomized, it provides exploratory 
evidence of telephone-based services for cancer populations. A recent study suggests that 
telephone-delivered cognitive behavioral therapy was comparable to face-to-face CBT for 
reducing anxiety and depression and improving coping skills in cancer patients (Watson, White, 
Lynch, & Mohammed, 2017). Furthermore, problem-solving interventions delivered via 
telephone have been effective in cancer patients as well (Watson et al., 2013).  
In sum, the literature supports the use of CBT-I as the first-line of treatment for insomnia 
in cancer patients and encourages the use of telehealth to disseminate and implement CBT-I to 
all populations. Thus, given the proliferation of telehealth technologies and the growing evidence 
favoring the delivery of CBT-I through telehealth, it is imperative to examine which telehealth 
modality would be most efficacious and feasible in cancer populations. To our knowledge, no 
study to date has evaluated the efficacy of telephone-delivered CBT-I in cancer patients.  
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Table 1.  
Summary of Studies Investigating Telehealth and CBT-I in Cancer Patients  
 
 
 
Study 
Sample 
Characteristics 
 
Allocation 
Diagnosis/ 
Stage 
Type of 
Telehealth 
Treatment 
Components 
 
Sessions 
 
Follow-up 
Ritterband et 
al., 2012 
Males and 
Females;      
Mean 56.7  
CBT-I = 14, 
WLC = 14 
State I-IV Internet-based 
SC, SR, SH, 
CR 
6 session over 9 
weeks (45-60 min) 
None  
Savard et al., 
2011 
Females; Mean 
51.5 (37-74) 
VCBT-I = 11  
Breast 
 Stage I-III 
Self-administered 
animated DVD + 
Booklet 
SC, SR, CR, 
SH, RP 
6 videos, weekly      
(60 minutes) + 1 
booklet 
3-month 
Savard et al., 
2014 
Females; Mean 
54.4 (18-75) 
Individual = 81, 
Video-based  = 
80, Control = 81 
Breast; 
Stages 0-III 
Self-administered 
animated DVD + 
Booklet 
SC, SR, CR, 
SH 
6 videos, weekly, 
(60 minutes) + 6 
booklet; 6 
individual sessions 
(50-minutes) 
None  
Savard et al., 
2016 
Females; Mean 
54.4 (18-75) 
Individual = 81, 
Video-based = 
80, Control = 81 
Stages 0-III 
Video-based 
(animated 60-
minute video + 6 
booklets) 
SC, SR, CR, 
SH 
6 sessions; 6 weeks 
(60 minutes)  
3-, 6-, and    
12-month 
Zhou et al., 
2017 
Males and 
females; Mean 
28.1 (15-40) 
In-person = 6, 
Videoconference 
= 4 
Leukemia/ 
Lymphoma, 
Solid Tumor 
Videoconference 
(Sessions 2 & 3) 
SR, SC, SH, 
CR 
3 sessions                      
(60 minutes) 
2- month 
Epstein & 
Dirksen, 2007 
Females; Mean 
57.1 (29-74) 
CBT-I = 34 
Control = 38 
Breast Stages 
I-III 
Combined group 
with 2  phone 
conversations  
SR, SC, SE, 
SH 
4 weekly groups 
and 2 weekly 
telephone sessions 
(60-120-minutes 
group & 15-30 
minutes telephone) 
None 
Note. Abbreviations: CBT-I, cognitive behavioral therapy for insomnia; WLC, wait list control; SC, stimulus control; SR, sleep restriction; SH, sleep 
hygiene; CR, cognitive restructuring; VCBT-I, video-based CBT-I; RP, relapse prevention; SE, sleep education.   
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Current Study 
Based on the existing scientific knowledge, technological advance and practice 
patterns, the current study aims to contribute to the growing literature on the use of telehealth 
to effectively disseminate CBT-I to cancer patients. The goals of the study are to test the 
efficacy and feasibility of a brief telephone-delivered CBT-I program among patients with 
different types of cancer diagnoses. Although the effectiveness of CBT-I has been established 
(Manber & Simpson, 2016; Morin et al., 2015; Siebern & Manber, 2011) and its effectiveness 
in cancer patients is well-documented by previous studies (Dirksen & Epstein, 2008; Espie et 
al., 2008; Garland, Rouleau, Campbell, Samuels, & Carlson, 2015; Howell et al., 2014), its 
efficacy using telehealth has yet to be established. In order to build the strongest empirical 
evidence, this study was undertaken as a randomized controlled trial comparing telephone-
delivered CBT-I (TeleCBT-I) to a treatment-as-usual control group and is reported in 
accordance with the CONSORT statement for non-pharmacological trials (Boutron et al., 
2017). 
As noted in the literature, the issue is no longer whether CBT-I is effective, but how to 
effectively disseminate it. Despite the evidence of CBT-I in reducing insomnia among cancer 
patients, CBT-I remains underutilized and largely inaccessible to cancer patients. Research 
demonstrated that insomnia is not routinely screened, assessed or diagnosed during the cancer 
treatment trajectory, and when diagnosed cancer patients are more likely to be offered 
medication treatment instead of a referral to non-pharmacological treatments (Siefert et al., 
2014). Unfortunately, those who are referred to non-pharmacological treatment, such as CBT-I 
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face substantial challenges to access treatment in a timely fashion. For example, CBT-I may be 
delayed due to limited availability of trained providers, transportation costs, treatment duration, 
and cost of face-to-face treatment sessions (Morin, 2010; Siefert et al., 2014; Sivertsen et al., 
2013). Aside from these common barriers, cancer patients face additional challenges to access 
CBT-I. For example, medical complications related to cancer treatment may limit their ability 
to engage in additional treatment services outside of their home or hospital. Furthermore, 
cancer patients may have exhausted social, financial, and work-related resources in their 
extensive cancer care.  
Given the barriers to delivering CBT-I to cancer patients, there is an urgent need to 
investigate alternative treatment delivery options to improve CBT-I dissemination to cancer 
patients. To date, only three studies have evaluated the use of telephone-delivered CBT-I in 
adult populations and found positive clinical outcomes (Arnedt et al., 2013; Bastien et al., 
2004; Holmqvist et al., 2014). However, no study has tested the use of telephone-delivered 
CBT-I in cancer patients.  
Using a randomized controlled trial design, this study examined the efficacy and 
feasibility of a brief telephone-delivered CBT-I program in cancer patients compared to a 
treatment-as-usual control group. For the purpose of this study, a four-week CBT-I program 
was adapted for cancer patients. The main aims were twofold: (1) to test the efficacy of 
TeleCBT-I in reducing insomnia symptoms at post-treatment and one-month follow-up, and 
(2) to evaluate the feasibility of TeleCBT-I in cancer patients. Based on preliminary evidence 
suggesting that CBT-I may improve other comorbid psychological symptoms, the study also 
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examined whether TeleCBT-I had an effect on fatigue, depression, anxiety, general 
functioning, and quality of life.  
 
The primary hypotheses were:  
(1) Compared to control group, cancer patients in the TeleCBT-I group would show 
improvements in insomnia severity, quality of sleep, and beliefs about sleep at 
post-treatment. 
 
(2) Compared to control group, TeleCBT-I group would report improvements in all 
sleep measures at one-month follow.   
 
(3) Those in the TeleCBT-I group would be actively engaged by attending the four 
treatment sessions over the telephone and completing their homework daily or 
almost daily.  
 
The secondary hypothesis was: 
(4) Compared to control group, TeleCBT-I group would show beneficial changes in 
fatigue, anxiety, depression, general functioning and quality of life.  
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CHAPTER THREE: RESEARCH DESIGN AND METHODOLOGY 
Participants  
Eligibility Criteria 
Patients met criteria to participate in the study if they were 18 years or older, were 
receiving medical treatment at Orlando Health UF Health Cancer Center (OH-UFCC), had a 
cancer diagnosis and concurrent diagnosis of insomnia. Insomnia diagnosis was assessed with 
the Structured Clinical Interview for DSM-5 Sleep Disorders Module (Taylor et al., 2018) and 
the Insomnia Severity Index (ISI) with a score of eight or higher (Buysse, Ancoli-Israel, 
Edinger, Lichstein, & Morin, 2006). Additional inclusion criteria were the ability to speak and 
read English. Exclusion criteria were other diagnosed sleep disorders (e.g., narcolepsy), as well 
as, other untreated pre-existing sleep disorders (e.g., sleep apnea), severe psychiatric diagnosis 
(e.g., schizophrenia), cognitive impairment or dementia, or neurological disorder, and active 
psychotic symptoms, suicidal ideation, intention or plan or substance use. Additionally, 
subjects were excluded if unable to attend at least three of the four TeleCBT-I sessions.  
Recruitment 
This study was reviewed and approved by the Orlando Regional Medical Center 
Internal Review Board and the University of Central Florida Internal Review Board. (See 
Appendix A). Participants were recruited from the patient population at Orlando Health UF 
Health Cancer Center (OH-UFCC) clinics. Recruitment flyers were displayed throughout the 
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different OH-UFCC clinics and distributed at group activities provided by the OH-UFCC’s 
Integrative Medicine Department (See Appendix B). Patients were identified and referred by 
their medical providers if presenting with insomnia related complaints. Additionally, patients 
were able to self-refer to participate in the study. Patients were first screened by telephone to 
determine study eligibility before enrollment. Providers were informed about the study and 
recruitment procedures during staff meetings, didactic or grand rounds presentations. 
Furthermore, an information letter was disseminated every three to four months to oncology 
physicians and providers explaining the study aims, eligibility criteria and recruitment 
procedures (See Appendix C). 
Among the patients that were approached (n = 184), 132 were deemed eligible to 
participate in the telephone screening. The telephone screening identified 53 patients that met 
criteria and were invited to complete a diagnostic clinical interview. A total of 47 diagnostic 
clinical interviews were completed and 39 patients were randomized to either the TeleCBT-I or 
control groups. Appendix D exhibits patient recruitment and study follow chart. 
Sample Size Justification 
A priori power analyses were performed to estimate the number of participants needed 
to test the primary hypotheses. Power analyses were computed with G Power 3.1.9.2. Previous 
research on telephone-delivered CBT-I reported large effect sizes ranging from .80 to 2.5. The 
number of participants needed to determine whether there is a mean difference between the 
CBT-I and the control group was computed with a significance level of 5%, statistical power of 
80%, and a to-be-detected population effect size of .80 as reported by Arnedt et al., 2015. The 
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estimated total sample needed was 42 (n = 21 each group). Then, the necessary sample size to 
test whether there are mean differences between groups for time and group x time interactions 
was evaluated with the same statistical parameters as above. However, to capture a wider range 
effect size, a medium effect size for analyses of variance was computed (.25) (Cohen, 1992). 
The estimated total sample was 28 (n = 14 each group). Thus, ascertaining treatment effects 
with statistical confidence should require at least 14 participants in each group. As with any 
study, the larger the sample size, the higher the confidence in its results.  
Telephone Screening  
Appendix E presents the script and screening used to identify potential study 
participants over the telephone. Details about the study were further explained during the 
telephone screening. If interested in participating in the study, patients were asked to complete 
the Sleep Disorders Questionnaire (SDQ) over the telephone. The SDQ measures the potential 
of meeting clinical criteria for insomnia. Those screened positively for a potential insomnia 
diagnosis were deemed pre-qualified for the study and were invited to complete an in-person 
diagnostic interview at OH-UFCC. Those who were not interested in participating in the study 
after pre-qualification were given the option to receive the same CBT-I program in person. 
None of the patients opted to receive the CBT-I in person.   
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Study Design and Procedures 
Study Design 
This is a two-group (intervention and control), prospective, randomized, single-center 
experimental design study. This study is part of a larger study with multiple follow-up 
assessments. Patients received four treatment sessions of TeleCBT-I provided by three trained 
graduate-level clinicians supervised by a licensed psychologist. Patients had the option to 
receive a booster session after completing the last treatment session, an option taken by only 
two patients. Sessions were between 45-75 minutes each. In most cases, the first session, which 
included psychoeducation and information about the structure and procedures of the study, and 
the last session, which explained treatment expectations, follow-up procedures and post 
assessment took longer. Each patient completed measures at screening, pre-treatment, post-
treatment and at one-month follow-up. The Consolidated Standards of Reporting Trails 
(CONSORT) and the recommendations for standard research and assessment of insomnia were 
applied (Buysse et al., 2006; Moher et al., 2010). Appendix F shows RCT procedures flow 
charts. 
Study Setting 
This study was conducted at Orlando Health UF Health Cancer Center (OH-UFCC) 
through its Integrative Medicine Department in Orlando, Florida. OH-UFCC is a state-
designated Cancer Center of Excellence, which is one of the most prestigious state recognitions 
provided by the State Surgeon General and Secretary of Health to cancer care entities (Florida 
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Department of Health, Office of Communications, 2015). Its state-of-the-art facilities serve 
over 80,000 patients annually and offer inpatient and outpatient services throughout locations 
at Orlando and Gainesville. For the purpose of this study, enrollment was limited to patients 
receiving treatment in Orlando, Florida.  
Diagnostic Clinical Interview  
During the diagnostic clinical interview patients provided consent to participate in the 
study, and completed a structured clinical interview, pre-treatment measures and an intake and 
demographic questionnaire. Appendix G presents the intake and demographic questionnaire. 
Part of the consent process included obtaining medical clearance from patients’ oncologist or 
medical provider. Thus, patients were asked to sign a medical clearance form, which was then 
used to collect the medical approval and clearance to participate in the study (See Appendix 
H).  
The Structured Clinical Interview for DSM-5 Sleep Disorders Module was used to 
diagnosed insomnia disorder and rule out other sleep disorders. Only those who met DSM-5 
criteria for insomnia disorder were enrolled in the study. Those assigned to the TeleCBT-I 
group were asked to complete a sleep diary for a minimum of two consecutive weeks prior to 
treatment. Patients were given the option to discontinue study participation at any time. 
Randomization and Allocation 
Eligible patients were randomized to either TeleCBT-I or control group. The RAND 
function of Microsoft Excel (Microsoft, version 2016) was used to generate unrestricted 
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randomly permutated codes prior to enrollment. Unrestricted or simple randomization 
assignment is similar to repeated coin tossing, and as a result, unequal group size is expected. 
In fact, it has been argued that forcing equal group size in simple randomized trials is merely 
cosmetic than scientifically (Schulz & Grimes, 2002). Thus, moderate discrepancy between 
groups was expected in accord to the essence of randomness as recommended by Schulz & 
Grimes (2002). Sealed envelopes were used to reveal allocation during the diagnostic 
interview. Initially, patients were randomized to three conditions (Group TeleCBT-I, 
Individual TeleCBT-I, and control group), but it was thereafter discontinued and the four 
patients that were assigned to the group TeleCBT-I format were re-assigned to individual 
TeleCBT-I.  
Brief TeleCBT-I Program 
After a comprehensive review of the literature, the brief TeleCBT-I program was 
developed using a multicomponent approach as tested in most clinical trials and clinical 
practices (Siebern & Manber, 2011). TeleCBT-I incorporated the most frequently used 
components of CBT-I: 1) sleep education, 2) sleep hygiene, 3) stimulus control, 4) sleep 
restriction, 5) cognitive restructuring, and 6) relaxation training (Manber & Simpson, 2016). 
Content components were condensed and separated into four sessions, instead of the usual 
eight to twelve CBT-I sessions. The resulting TeleCBT-I program consisted of four treatment 
sessions delivered once per week over the course of four weeks.  
TeleCBT-I included a patient manual and workbook that was mailed to patients after 
completing the sleep diary and prior to initiating treatment. The manual was developed based 
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on existing CBT-I protocols (Edinger & Carney, 2008, 2015; Manber & Simpson, 2016). 
Additionally, it was tailored to address the unique needs of cancer patients by including 
scientific knowledge of how poor sleep affects patients with cancer and cancer survivors. 
Relevant information about patients’ experiences with cancer treatment and poor sleep were 
also included throughout the different components. For example, cognitive restructuring 
included examples of dysfunctional thoughts of how lack of sleep would affect their health and 
cancer treatment. Table 2 presents an outline of the brief TeleCBT-I program components.  
  
25 
 
Table 2. 
TeleCBT-I Program Outline 
 
Week Outline 
1  Welcoming and participant introductions 
 Overview of TeleCBT-I program and study protocol 
 Sleep education  
 Sleep hygiene, part 1 
 Stimulus control 
 Review sleep diary  
 Set goals and provide week assignment 
 
2  Review of session 1 and homework 
 Review sleep diary 
 Sleep hygiene, part 2 
 Relaxation techniques 
 Sleep restriction 
 Development of new sleep schedule 
 Set goals and provide week assignment 
 
3  Review of session 2 and homework 
 Review sleep diary 
 Adjust sleep schedule and calculate sleep efficiency 
 Cognitive restructuring 
 Set goals and provide week assignment 
 
4  Review of sessions 1 - 3 and homework 
 Review of sleep diary 
 Review and adjust sleep schedule as needed 
 Discuss sleep medications side effects and tapering strategy 
 Relapse prevention  
 Complete post-treatment measures 
 Review follow-up plan and schedule 
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Control Group 
Patients allocated to the control group continued receiving treatment as usual. Patients 
were told that they needed to complete two sets of measures before beginning TeleCBT-I. 
Patients completed post-treatment and follow-up measures over the telephone at four- and 
eight-weeks, respectively. Patients were also given the choice to complete their measures in 
person or by mail. After completing the one-month follow-up measures, patients allocated to 
the control group were offered TeleCBT-I following the same procedures as those in the 
TeleCBT-I group.  
Telephone Equipment and Protocol 
The TeleCBT-I program was provided over the telephone using the OH-UFCC 
telephone service. Patients used their personal phones to participate in the sessions with no 
additional cost to them. Patients were asked to allot 60 to 90 minutes for the telephone-
delivered CBT-I sessions. Safety measures were taken following telehealth guidelines 
recommendations. Specifically, patients provided information of current location and another 
telephone number to contact them in the event the telephone call was disconnected. Patients 
were also asked to ensure privacy by taking the telephone call from a private space (e.g., non-
shared space within their home or office), and avoiding using the speaker mode if there is a 
possibility that another person could hear them.  
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Measures 
Screening 
Sleep Disorders Questionnaire (SDQ; Douglass et al., 1994). The SDQ includes 18 
items designed to identify those who: 1) meet criteria for a sleep disorder, 2) report problems 
with sleep and 3) do not report sleep problems. Patients were asked to answer each question 
using a Likert scale ranging from 1 (Never) to 5 (Always). The SDQ has a sensitivity of 95% 
and specificity of 87% for insomnia. The SDQ has been used studies with cancer patients, but 
reliability scores were not reported (Garland, Carlson, Antle, Samuels, & Campbell, 2011). 
Structured Clinical Interview 
 The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition Sleep Disorders (SCISD; Taylor et al., 2018). The SCISD is a brief 
clinician administered clinical interview that includes 20 to 51 questions and takes 10 to 20 
minutes to administer. The interview assesses nine major sleep disorders, including insomnia 
as specified in the DSM-5. Taylor et al., (2018) reported the SCISD had an excellent interrater 
reliability for insomnia (1.0).  
Sleep Measures  
Insomnia Severity Index (ISI; Morin, 1993). The ISI is a brief measure of subjective 
sleep complaints and associated distress. The ISI examines global severity of insomnia based 
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on difficulty initiating or maintain sleep, and degree of dissatisfaction and daytime impairment 
associated with insomnia. It is comprised of seven items rated on 5-point Likert scale ranging 
from 0 (None) to 4 (Very Severe). Higher scores indicate greater impairment and a score of 8 
indicates possible insomnia. The ISI has been shown to have high internal consistency 
(Cronbach’s alpha = .90-.91) (Morin, Belleville, Bélanger, & Ivers, 2011) and has been 
validated for use with cancer patients (Cronbach’s alpha = .90) (M. H. Savard, Savard, Simard, 
& Ivers, 2005). The ISI has also been found to be sensitive to therapeutic changes (Morin, 
Beaulieu-Bonneau, LeBlanc, & Savard, 2005). The Cronbach’s alpha in this study was .53. 
Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989). The PSQI consists of 19 items and measures seven component scores (subjective sleep 
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of 
sleeping medication, and daytime dysfunction) and a global score. Questions are scored on a 0 
to 3 scale over a period of one-month. Evidence supports its sensitivity and specificity in 
detecting good and poor sleep quality (Garland et al., 2011). In a previous study, the 
Cronbach’s alpha was .80 (Garland et al., 2011). In this study the Cronbach’s alpha was .44. 
Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS-16; Morin, Vallières, & 
Ivers, 2007). The DBAS-16 is an abbreviated measure designed to assess the disrupted 
cognition often seen in persons with sleep disturbance. Patients were asked to indicate the 
extent to which they agree with the statement on a Likert scale ranging from 0 (strongly 
disagree) to 10 (strongly agree). Scores of 4 or greater suggest unrealistic expectations for 
sleep or that dysfunctional thoughts about sleep have become a factor in the sleep problem. 
The DBAS-16 has been shown to have adequate internal consistency (Cronbach’s alpha = .77), 
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and has been validated for use in different insomnia subgroups (Edinger & Carney, 2015).  The 
Cronbach’s alpha in this study was .79. 
Sleep Diary (CSD; Carney et al., 2012). Sleep diaries are considered a reliable and 
valid measure of insomnia symptoms. The CSD was used in this study at pre-treatment and 
throughout the course of TeleCBT-I. The sleep diary provides night-by-night account of sleep 
pattern and quality of sleep. The sleep diary was used to calculate a subjective report of sleep 
efficiency throughout the course of TeleCBT-I.  
Psychological Variables  
Fatigue Symptom Inventory (FSI; Hann, Denniston, & Baker, 2000). The FSI is a 14-
item self-report measure designed to assess physical and psychological aspects of fatigue, 
including perceived severity, frequency, and daily pattern of fatigue as well as its perceived 
interference with quality of life. Severity is measured on a separate 11-point scale (0 = not at 
all fatigued; 10 = as fatigued as I could be) that assess most, least, and average fatigue in the 
past week, as well as, current fatigue. The FSI has been validated with males and females with 
cancer diagnosis. Previous research determined that a mean score of 3 or greater indicate 
clinically meaningful fatigue. The Cronbach’s alpha in a previous study was .95 (Stein, 
Jacobsen, Blanchard, & Thors, 2004). In this study the Cronbach’s alpha was .92. 
Functional Assessment of Cancer Therapy-General, Version 4 (FACT-G; Cella et al., 
1993). The FACT-G is a 27-item instrument that measures four primary quality of life 
domains: Physical well-being (PWB), Social/Family well-being (SWB), Emotional wellbeing 
(EBW), and Functional well-being (FWB) The statements use a 5-point rating scale (0 = Not at 
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all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). Sample items include: 
“I feel sad” and “I have accepted my illness.” FACT-G total score is computed as the sum of 
the four subscale scores with a possible range of 0-108 points. Higher scores are indicative of 
less dysfunction. In this study, missing values were not manipulated as the answer response for 
each patient was over 80% (more than 22 of 28 items). Normative data of adult cancer patients 
(N = 2,236) was used to determine better functional well-being for each subscale and 
composite score as follows: PWB (Normal, M = 16-27; Dysfunctional, M ≤ 15, Better 
Functioning, M ≥ 28), SWB (Normal, M = 17-22; Dysfunctional, M ≤ 16, Better functioning, 
M ≥ 23), EWB (Normal, M = 15-18; Dysfunctional, M ≤ 14, Better functioning, M ≥ 19), FWB 
(Normal, M = 13-19; Dysfunctional, M ≤ 12, Better functioning, M ≥ 20), and FACT General 
(Normal, M = 65-81; Dysfunctional, M ≤ 64, Better functioning, M ≥ 82) (Cella, 2007). The 
instrument developers reported a Cronbach alpha of .89. In this study the Cronbach’s alpha 
was .44. 
Quality of Life for Cancer Survivor Version (QOL-CSV; Ferrell, Hassey Dow, & 
Grant, 1995). The QOL-CSV was designed to measure the specific concerns of long-term 
cancer patients. The QOL-CSV is based on previous versions of the QOL instrument 
developed by researchers at the City of Hope National Medical Centre (Grant, Padilla, and 
Ferrell). The QOL-CSV consists of 41 items representing the four domains of quality of life 
incorporating physical, psychological, social, and spiritual well-being. Each item is rated on an 
anchored scale from 0 to 10. The higher the scores the better quality of life the individual 
endorses (Ferrell, Hassey Dow & Grant, 1995). In a previous study, the Cronbach’s alpha was 
.93 (B. Ferrell, Hanson, & Grant, 2013). The Cronbach’s alpha in this study was .80. 
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Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983). The HADS 
consists of seven-item anxiety and depression subscales. Scores ranged from 0-3 with 21 as the 
maximum score for each subscale. Higher scores reflect higher anxiety or depressive 
symptoms. Scores between 0-7 = Normal, 8-10 = Borderline abnormal (borderline case) and 
11-21 = Abnormal (case). Zigmond and Snaith (1983) reported a Cronbach alpha of .85 for the 
anxiety and .83 for the depression subscale, respectively. In this study the Cronbach’s alpha 
were .86 for the overall scale, .76 for the anxiety subscale and .85 for the depression subscale.  
Feasibility  
Treatment Satisfaction Questionnaire (TSQ). The TSQ was developed for this study to 
assess patients' overall experience and satisfaction with the TeleCBT-I program (see Appendix 
I). The TSQ was administered at post-treatment only and consisted of closed- and open-ended 
questions. Patients were asked to rate nine statements evaluating specific aspects of the 
treatment experience. Statements were rated using a 3-point scale from 0 (Strongly Disagree) 
to 3 (Strongly Agree). Sample items include: “The program has motivated me to work on my 
sleep problems” and “I gained greater understanding of my sleep problem(s).” Items were 
averaged and summed to provide a total score. Negative scored items were reversed and higher 
scores were indicative of positive experience. Four statements examined clinicians’ 
performance as perceived by patients using a 3-point scale from 0 (Strongly Disagree) to 3 
(Strongly Agree). Sample items include: “The practitioner understood my sleep problems and 
concerns” and “The practitioner was good at her/his job.” Items were averaged and summed to 
compute a composite score of clinician’s performance.  
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Additionally, the TSQ measured treatment adherence based on the number of 
completed sessions and by asking patients how often they completed homework and practiced 
the treatment recommendations at post-treatment. Specifically, patients were asked “Overall, 
how often did you practice the suggested homework or daily practice?” with five possible 
answers (daily, almost daily [4-6 days/week], occasionally [1-3 days/week], rarely [0-1 
days/week], never ([0 day/week]). Further, overall satisfaction with the TeleCBT-I program 
and helpfulness of program manual were each evaluated with one item using a 4-point scale 
from 0 (Very Dissatisfied or helpful) to 3 (Very Satisfied or Helpful). Moreover, patients were 
asked whether they would recommend the TeleCBT-I program to other patients using a 4-point 
scale from 0 (Not at all likely) to 4 (Extremely likely). 
Qualitative questions to ascertain what aspects of the program patients liked or disliked 
included: “What did you find most helpful about the Sleeping Well Program?” and “What did 
you find least helpful about the Sleeping Well Program?” Responses were reviewed to identify 
major themes. Lastly, the TSQ included questions to determine major changes in patients’ 
health, treatment and life circumstances that could affect treatment outcomes.  
Demographics 
Baseline demographic and medical characteristics included demographic (age, marital 
status, employment) and medical information (history of sleep problems, months since 
diagnosis, cancer type, cancer location, cancer stage, and treatment). 
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Post-treatment  
All patients were asked to complete the post-treatment measures. The post-treatment 
measures were similar as the pre-treatment measures with the exception of the TSQ, which was 
developed for this study. Only those in the TeleCBT-I group were asked to complete the TSQ. 
The TeleCBT-I group completed the post-treatment measures during the last portion of their 
fourth treatment session, while the control group completed the post-treatment measures four 
weeks after the clinical interview. Patients were given the option to complete the measures in 
person or by phone. Following, patients were mailed a letter thanking them for their 
participation in the study. In addition, the letter included general sleep recommendations and 
patient’s individualized scores on insomnia severity, sleep quality, depression and anxiety at 
pre- and post-treatment. Appendix J shows the template for the end treatment letter.  
One-Month Follow-Up 
Given that RCTs often estimate treatment effects by evaluating follow-up outcomes 
between treatment groups (Karlsson & Bergmark, 2015), both treatment groups were asked to 
complete follow-up measures. Patients in the TeleCBT-I group completed follow-up measures 
four weeks after completing treatment, while the control group completed follow-up measures 
four weeks after post-measures. Patients in the control group were offered the TeleCBT-I 
treatment after completing follow-up measures.  
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Statistical Analyses 
Data Preparation 
All analyses were performed using SPSS version 25 (IBM). Data was entered and 
verified independently by two research assistants. Examination of missing data, outliers and 
distributions was performed using standard procedures as outlined by Tabachnick & Fidell 
(2013). After inspecting data for accuracy, missing values were evaluated. Missing values 
detected were minimal and accounted for less than 5% on each of the few variables that had 
missing values. As a result, no missing data was imputed and missing cases were excluded 
using listwise deletion.  
Normality was assessed by evaluating plots, and computing skewness and kurtosis. 
Considering the small sample size of this study (N < 50), skewness and kurtosis were evaluated 
using conventional and conservative standards as recommended by (Tabachnick & Fidell, 
2007; Tabachnick & Fidell, 2013). Except for physical well-being, all variables had skewness 
and kurtosis scores below the absolute value of 3.29. Outliers were identified by evaluating 
studentized residuals at a multivariable level, including the two treatment groups and three 
time points together. Studentized residual values greater than the absolute value of 3.00 were 
considered outliers. Using this parameter, one case was identified as an outlier on HADS 
anxiety and QOL physical subscales at one-month follow-up.  
Based on the pattern of relatively normal distribution across variables, parametric 
statistics were computed. Outliers were removed from analyses as appropriate and results with 
and without outliers were reported. The assumption of sphericity was evaluated using 
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Mauchly’s test to determine whether the variances of differences were roughly equal. The 
Greenhouse-Geisser estimate was used when the sphericity assumption was not met as per 
recommended statistical parameters (Field, 2013; Tabachnick & Fidell, 2013). 
Data Analyses 
The TeleCBT-I and control groups were compared using t-tests, chi-square or Fisher’s 
exact test analyses, as appropriate, on demographic, clinical variables and outcome variables at 
pre-treatment. Repeated measures analysis of variance (RM ANOVA) was used to evaluate the 
difference in the rates of change between the TeleCBT-I and control groups over the three time 
points. The basic model of group (coded as TeleCBT-I =1 and Control = 0), Time (pre-
treatment, post-treatment, follow-up), and group x time as fixed effects. The outcome models 
included a treatment main effect to determine whether there is an overall difference between 
groups and a time main effect to determine whether scores changed over time. The main 
interest was in the group x time interaction effects to address the hypotheses that change by 
time differed by treatment group. Measures that demonstrated a significant treatment x time 
interaction were included in follow-up analyses.  
Follow-up analyses followed the general linear model with three time points. 
Bonferroni adjusted post hoc tests were conducted to examine treatment differences in changes 
from pre-treatment to post-treatment and changes from pre-treatment to follow-up. 
Additionally, to demonstrate clinically meaningful changes at different time points, the 
insomnia severity scores were coded using its clinical cut off as: No clinically significant 
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insomnia (0-7), Subthreshold insomnia (8-14), Clinical insomnia (moderate severity) (15-21), 
and Clinical insomnia (severe) (22-28).  
Effect Size  
Partial eta
2
 is commonly used in ANOVA designs as a measure of effect size and is 
often recommended particularly for repeated measures analyses (Field, 2013). In this study, 
partial eta
2
 was used to estimate the percentage of variance in each of the effects (main effects 
and interactions). Results are interpreted as percentages of variance by moving the decimal 
point two places to the right. In addition, partial eta
2
 is interpreted using cut offs for the 
magnitude of the effect as follows: .01 (small), .06 (medium) and .14 (large) (Cohen, 1988). 
Hedges’ g was computed as an additional measure to estimate the magnitude of effect size by 
treatment groups. Hedges’ g was chosen instead of Cohen’s d because it accounts for small and 
unequal sample sizes (Hand, 2012). Hedges’ g is interpreted using the Cohen’s criteria for 
small (0.2), medium (0.5) and large (0.8) treatment effects.  
Sample Size and Power Analyses 
Repeated measures designs offer several benefits over independent measures designs 
(Field, 2013). Broadly, by including the same participants within each condition of the 
independent variables, the variance and bias caused individual differences is reduced. The 
results of the error term tend to be smaller producing greater statistical power. That is, if an 
effect exists, it is more likely to be detected. Lastly, repeated measures designs require a 
smaller number of participants (Field, 2013). Considering the merits of repeated measures 
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designed mentioned above, sensitivity analyses were computed to determine the population 
effect size for the study sample (Cohen, 1988).  
Power analyses were computed with G Power 3.1.9.2. With an alpha level of .05, 
statistical power of .80, and a total sample size of 35, effect sizes > d = 0.86 could be detected 
when evaluating whether there is a mean difference between the TeleCBT-I and the control 
group (Cohen, 1988). Sensitivity analyses were also computed for the evaluation of mean 
differences between groups for time and group x time interactions using standard parameters 
(alpha = .05, power = .80) and sample size of 35 for three measures and two groups. With these 
statistical parameters, an effect size > d = 0.40 could be detected (Cohen, 1988).  
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Intention to Treat Analysis 
The intention to treat (ITT) analysis is typically recommended for randomized 
controlled trials (Fisher et al., 2017; Ten Have et al., 2009) as it reflects real-world clinical 
practices where patients discontinue treatment or do not engage in treatment at all. ITT 
estimates treatment effects based on all randomized participants regardless of whether they 
adhered or completed the assigned treatment (Fisher et al., 2017; Hernán & Hernández-Díaz, 
2012). The application of ITT analysis is critical for studies with substantial missing data 
resulting from lack of adherence and drop outs (Hernán & Hernández-Díaz, 2012). However, 
ITT also has its disadvantages as it may dilute the effects of a treatment due to noncompliance, 
and add heterogeneity in the sample by mixing together participants who are noncompliant, 
compliant, and drop outs. Further, it does not assess treatment efficacy accurately as it 
considers participants who have not received the intervention or have not completed the entire 
dose of an intervention or treatment (Gupta, 2011).  
One alternative to ITT analysis is the as per-protocol (PP) analysis. PP analysis 
includes a subset of the ITT population by including participants who completed treatment 
without major protocol deviations and excluding those who did not complete treatment or did 
not receive the treatment (Gupta, 2011; Hernán & Hernández-Díaz, 2012). In fact, researchers 
have argued that it is advisable to exclude participants post-randomization if they did not 
receive the treatment and their allocation does not impact the chances of other participants to 
receive the treatment (Fergusson, Aaron, Guyatt, & Hébert, 2002). Thus, while ITT tends to 
make two treatments look similar, one advantage of PP is that it does a better job at reflecting 
treatment differences by analyzing data from participants who completed treatment and 
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provided outcome measures. Although PP estimates the true efficacy of a treatment, it may 
provide exaggerated treatment effects. Given the above mentioned strengths and limitations of 
these statistical analyses, the CONSORT guidelines for parallel group RCTs recommend that 
both ITT and PP analyses should be reported to allow participants to better interpret treatment 
effects (Moher et al., 2010) 
Considering the entire randomized population for this study (N = 39), 35 patients 
completed pre-and post-treatment measures, 3 did not receive the TeleCBT-I treatment and 
only one 1 patient dropped out without completing the treatment, PP analysis was deemed 
more appropriate as the main goal of the study is to evaluate treatment efficacy. ITT analysis 
was also performed to adhere to the CONSORT guidelines and ascertain the potential for 
selection bias (Moher et al., 2010). ITT analysis was conducted using the last observation 
carried forward (LOCF) for the four patients who did not complete the intervention and post-
treatment measures. Results from ITT analysis are presented after the main PP results.  
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CHAPTER FOUR: RESULTS 
Demographic and Sample Characteristics 
Patients were recruited in the study from January 2018 through March 2019. The total 
sample comprised 35 cancer patients who completed pre-treatment and post-treatment 
measures. Most patients were females (n = 30, 85.71%) with a mean age of 55.26 years (SD = 
10.72; range 29-74). Over half of the sample self-identified as non-Hispanic Whites (n = 20, 
57.1%), while a quarter as Hispanics (n = 9, 25.7%), and a small portion as Blacks/African 
Americans (n = 4, 11.4%) and mixed race/ethnicity (n = 2, 5.7%). Marital status was fairly 
distributed as patients reported being currently married (n = 13, 37.1%), divorced (n = 10, 
28.6%), single (n = 8, 22.9%) or widowed (n = 4, 11.4%). Most patients were either full-time 
employed (n = 13, 37.1%) or retired (n = 12, 34.3%). Almost the entire sample had completed 
some college, higher education or more (n = 33, 94.3%). Patients’ reported personal annual 
income ranged from less than $25,000 (n = 12, 34.2%) to $50,000 or more (n = 14, 40%).   
Table 3 depicts the demographic and sample characteristics by treatment group. There 
were no statistically significant differences between treatment groups on demographic and 
sample characteristics variables, except for personal income. 
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Table 3. 
Demographic and sample characteristics by treatment group 
 
 TeleCBT-I 
(n = 19) 
 Control 
(n = 16) 
 
 
Variables 
Mean 
No 
SD 
% 
 Mean 
No 
SD 
% 
 
p 
Age (years) 56.37 9.64  53.94 12.07 .512 
 Range = 36 to 71  Range = 29 to 74  
Sex       .642 
     Female 17 89.5  13 81.3  
Race/Ethnicity       .377 
     Non-Hispanic White 12 63.2  8 50  
     African American 2 10.5  2 12.5  
     Hispanic  3 15.8  6 37.5  
     Mixed 2 10.5  - -  
Marital status      .440 
     Single 3 15.8  5 31.3  
     Married  6 31.6  7 43.8  
     Divorced  7 36.8  3 18.8  
     Widowed 3 15.8  1 6.3  
Highest Level of Education      .239 
     High School or GED - -  2 12.5  
     Some College 5 26.3  5 31.3  
     Bachelor’s degree 7 36.8  7 43.8  
     Master’s degree  7 36.8  2 12.5  
Employment      .490 
     Part-time 2 10.5  2 12.5  
     Full-time 8 42.1  5 31.3  
     Unemployed 2 10.6  1 6.3  
     Retired  7 36.8  5 31.3  
     Disabled  - -  3 18.8  
Income       .048* 
     Less than $15,000 2 10.5  4 25  
     15,000-24,999 3 15.8  3 18.8  
     25,000-34,999 - -  4 25  
     35,000-49,999 4 21.1  - -  
     50,000-74,999 4 21.1  1 6.3  
     75,000 or more  
     Missing 
6 
- 
31.6 
- 
 3 
1 
18.8 
6.3 
 
Note. Significance tests for continuous variables were determined with independent samples t-tests (2-
tailed), while Fisher’s exact tests were used for dichotomous and categorical variables.  
Abbreviations: TeleCBT-I, Telephone-delivered cognitive behavioral therapy for insomnia; SD, standard 
deviation; No, frequency; %, percentage; GED, general educational development test.  
Income (n = 34). 
*p < .05. 
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Similarly, there was no difference between treatment groups on cancer related 
variables. In the total sample, patients reported having a cancer diagnosis of stage I (n = 12, 
34.3%), stage II (n = 7, 20%), state III (n = 5, 14.3%), stage IV (n = 5, 14.3%), and some did 
not know their cancer stage diagnosis (n = 6, 17.13%). Most patients reported a breast cancer 
diagnosis (n = 20, 57.1%) and were diagnosed either two or more years ago (n = 17, 48.6%) or 
less than a year ago (n = 12, 34.3%).   
In terms of past and current cancer treatment, most patients reported that they received 
surgery (n = 27, 77.1%), chemotherapy (n = 24, 68.6%), radiotherapy (n = 24, 68.6%), and 
hormonal therapy (n = 15, 42.9%). However, while a significant portion of patients were not 
undergoing cancer treatment at the time of the study (n = 16, 45.7%), more than half were 
receiving hormonal therapy (n = 9, 25.7%), chemotherapy (n = 4, 11.4%), radiotherapy (n = 4, 
11.4%), and/or surgery (n = 4, 11.4%). Table 4 shows the cancer related information by 
treatment group. 
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 Table 4 
Cancer Related Information by Treatment Group 
 
  
 TeleCBT-I 
(n = 19) 
 Control 
(n = 16) 
 
 
Variables No %  No % p 
Cancer stage      .369 
     Stage I 7 36.8  5 31.3  
     Stage II 6 26.3  2 12.5  
     Stage III  3 15.8  2 12.5  
     Stage IV 3 15.8  2 12.5  
     Don’t know  1 5.3  5 31.3  
Time since cancer diagnosis      .319 
     Less than one year 6 31.6  6 37.5  
     One to two years ago 5 26.3  1 6.3  
     Two or more years ago 8 42.1  9 56.3  
Cancer location      .406 
     Breast  13 68.4  7 43.8  
     Brain  1 5.3  3 18.8  
     Skin  - -  1 6.3  
     Colon  1 5.3  1 6.3  
     Head and Neck 1 5.3  2 12.5  
     Kidney  - -  1 6.3  
     Musculoskeletal - -  1 6.3  
     Lung  1 5.3  - -  
     Blood 1 5.3  - -  
     Ovarian  1 5.3  - -  
Past cancer treatments       
     Chemotherapy 15 78.9  9 56.3 .273 
     Radiation therapy 13 68.4  11 68.8 >.05 
     Surgery 14 73.7  13 81.3 .700 
     Hormone therapy 10 52.6  5 31.3 .306 
     No past treatment - -  1 6.3 .457 
Current cancer treatments          
     Chemotherapy 3 15.8  1 6.3 .608 
     Radiation Therapy 2 10.5  2 12.5 >.05 
     Surgery 2 10.5  2 12.5 >.05 
     Hormone therapy 7 36.8  2 12.5 .135 
    No current treatment 6 31.6  10 62.5 .095 
Note. Differences by group were determined with Chi-square and Fisher’s exact tests. 
Abbreviations: TeleCBT-I, Telephone-delivered cognitive behavioral therapy for insomnia; SD, standard 
deviation; No = Frequency; % = Percentage. 
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Pre-treatment Characteristics 
Sleep Variables 
At pre-treatment, the average insomnia severity score as measured by the ISI was 17.66 
(SD = 4.07) indicating clinically significant insomnia with moderate severity for the entire 
sample. The average sleep quality as measured by the PSQI was 11.83 (SD = 3.44) and 
indicated poor sleep quality. Patients reported dysfunctional beliefs about sleep as measured by 
the DBAS-16 with a mean score of 5.24 (SD = 1.62). Further, about half of the patients were 
taking prescribed sleep medications prior to treatment (n = 18, 51.4%). There was no 
difference between groups on any of the sleep outcome variables at pre-treatment. Table 5 
depicts the sleep outcome measures at pre-treatment for each treatment group.  
 
 
Table 5. 
Scores on Sleep Measures and Group Differences at Pre-treatment  
 
  
 TeleCBT-I 
(n = 19) 
Control 
(n = 16) 
   
Variables Mean SD Mean SD t (33) / 2 p 95% CI 
 
ISI 
 
17.79 
 
3.57 
 
17.50 
 
4.71 
 
.207 
 
.837 
 
[-2.56,  3.14] 
PSQI 11.95 3.05 11.69 3.96 .219 .828 [-2.15,  2.67] 
DBAS-16 4.98 1.50 5.55 1.75 -1.02 .315 [-1.68,  0.56] 
Sleep Medication % (n) 52.6 10 8 50 .024 > .05  
 
Note. Significance tests were determined with independent samples t-tests (2-tailed) or chi-square tests. 
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; SD, standard 
deviation; ISI, insomnia severity inventory; PSQI, Pittsburgh sleep quality index; DBAS-16, dysfunctional 
beliefs about sleep.  
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Psychological Variables  
In the entire sample, patients reported scores higher than three, indicating clinically 
significant levels of fatigue at pre-treatment (M = 4.74, SD = 2.01) as measured by the FSI. 
However, patients reported no clinical levels of anxiety (M = 8.14, SD = 4.35) and depression 
(M = 6.17, SD = 4.23) as measured by the HADS.  
In terms of functional assessment of health-related quality of life, the FACT-G pre-
treatment scores were examined using the normative data for cancer patients (Brucker, Yost, 
Cashy, Webster, & Cella, 2005). In the total sample, patients reported normal levels of general 
functioning (M =72.03, SD = 17.43), physical well-being (M = 19.37, SD = 4.96), social/family 
well-being (M = 19, SD = 6.27), emotional well-being (M = 17.06, SD = 4.63), and functional 
well-being (M = 16.6, SD = 5.31).  
In terms of quality of life, patients reported scores slightly greater than the midpoint on 
the quality of life measure (QOL-CS) suggesting positive, but not optimal levels of overall 
quality of life (M = 5.72, SD = 1.45), physical QOL (M = 6.26, SD = 1.70), psychological QOL 
(M = 5.84, SD = 1.96), social QOL (M = 5.82, SD = 2.11), and spiritual QOL (M = 6.05, SD = 
2.15). Table 6 presents the results for the psychological outcome variables by treatment group. 
No differences were found between groups in all psychological variables.  
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Table 6. 
Scores on Psychological Measures and Group Differences at Pre-treatment 
  
 TeleCBT-I 
(n = 19) 
Control 
(n = 16) 
   
Variables Mean SD Mean SD t (33) p 95% CI 
        
FSI  4.60 1.62 4.90 2.44 -.422 .676 [-1.69, 1.11] 
HADS-Depression 5.58 4.80 6.88 3.44 -.902 .374 [-4.22, 1.63] 
HADS-Anxiety 7.89 4.22 8.44 4.62 -.363 .719 [-3.58, 2.50] 
FACT-General 71.37 19.21 72.81 15.63 -.241 .811 [-13.64, 10.76] 
   Physical well-being 19.79 5.13 18.88 4.87 .538 .594 [-2.55, 4.37] 
   Social/Family well-being 18.42 6.68 19.69 5.88 -.590 .559 [-5.64, 3.10] 
   Emotional well-being 17.11 4.99 17 4.32 .066 .948 [-3.14, 3.35] 
   Functional well-being 16 5.88 17.31 4.63 -.723 .475 [-5.00, 2.38] 
QOL-CSV Total 5.83 1.50 5.59 1.42 .469 .642 [-.78, 1.25] 
   Physical 6.23 1.64 6.3 1.81 -.115 .909 [-1.26, 1.12] 
   Psychological 5.86 2.25 5.82 1.63 .059 .953 [-1.34, 1.42] 
   Social  6.09 1.82 5.49 2.43 .826 .415 [-.87, 2.05] 
   Spiritual  5.96 2.30 6.16 2.02 -.272 .787 [-1.70, 1.30] 
        
Note. Significance tests were determined with independent samples t-tests (2-tailed). 
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; FSI, fatigue 
symptom inventory; HADS-Depression, depression subscale of hospital anxiety and depression scale; HADS-
Anxiety, anxiety subscale of hospital anxiety and depression scale; FACT, functional assessment of cancer 
therapy; QOL-CSV, quality of life patient/cancer survivor version. 
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Post-treatment Outcomes  
Sleep Variables 
Insomnia Severity  
The TeleCBT-I intervention resulted in significantly greater improvements in insomnia 
severity than the control group. The ISI mean decreased from 17.79 (SD = 3.57) to 7.58 (SD = 
3.78) in the TeleCBT-I group reaching no clinically significant level at post-treatment. 
However, the ISI mean decreased from 17.50 (SD = 4.71) to 14.88 (SD = 5.82) in the control 
group sustaining clinically significant levels of insomnia severity at post-treatment. Hedges’ g 
of the TeleCBT-I group was 2.72, while the Hedges’ g of the control group was 0.48. There 
was significant within-subjects main effect across pre- and post-treatments, F(1, 33) = 81.01, p 
< .001, partial 2  = .711, and a significant main effect between treatment groups, F(1, 33) = 
6.8, p = .014, partial 2  = .171. The significant Group x Time interaction, F(1, 33) = 28.29, p < 
.001, partial 2  = .462, revealed that both groups reported decreased symptoms of insomnia 
severity at post-treatment. Post hoc comparisons revealed statistically significant differences 
between pre-treatment and post-treatment in both treatment groups, TeleCBT-I (p < .001) and 
control (p = .018). Figure 1 shows the mean scores on insomnia severity for the TeleCBT-I and 
control groups from pre-treatment to post-treatment.  
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Figure 1. 
Scores on Insomnia Severity by Group at Pre-treatment and Post-treatment 
Note. Error bars represent 95% confidence intervals. 
*p < .05, ***p < .001. 
 
 
To examine meaningful clinical change in insomnia severity scores as a function of ISI 
clinical cut offs (0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia, 15-21 
= clinical insomnia/moderate severity, 22-28 = clinical insomnia/severe) from pre- to post-
treatment, Fisher’s exact tests were computed and demonstrated no difference between 
TeleCBT-I and control groups at pre-treatment. However, a statistical significance was 
observed between treatment groups at post-treatment where those in the TeleCBT-I group were 
more likely to endorse no clinically significant insomnia compared to control group (n = 12, 
63.2% vs. n = 1, 6.3%), respectively (p = .001).  
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Sleep Quality  
As shown in Figure 2, the TeleCBT-I group reported significantly greater 
improvements in sleep quality at post-treatment compared to the control group. The TeleCBT-I 
group showed a significant reduction from pre-treatment (M = 11.95, SD = 3.05) to post-
treatment (M = 6, SD = 2.36), while the control group showed virtually no change from pre-
treatment (M = 11.69, SD = 3.96) to post-treatment (M = 11.06, SD = 4.06) in sleep quality. 
Hedges’ g of the TeleCBT-I group was 2.14, while the Hedges’ g of the control group was 
0.15. There was significant within-subjects main effect across pre- and post-treatments, F(1, 
33) = 37.67, p < .001, partial 2  = .533, and a significant main effect between treatment 
groups, F(1, 33) = 5.65, p = .023, partial 2  = .146. There was also a significant Group x Time 
interaction, F(1, 33) = 24.7, p < .001, partial 2  = .428. Post hoc comparisons revealed a 
statistically significant difference between pre-treatment and post-treatment in the TeleCBT-I 
group only (p < .001).  
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Figure 2.  
Scores on Sleep Quality by Group at Pre-treatment and Post-treatment 
Note. Error bars represent 95% confidence intervals. 
***p < .001. 
 
Dysfunctional Beliefs about Sleep  
The TeleCBT-I group showed reduced dysfunctional sleep beliefs from pre-treatment 
(M = 4.98, SD = 1.50) to post-treatment (M = 3.28, SD = 1.65), while the control group showed 
slightly similar levels of dysfunctional sleep beliefs from pre-treatment (M = 5.55, SD = 1.75) 
to post-treatment (M = 5.01, SD = 1.99). Hedges’ g of the TeleCBT-I group was 1.06, while 
the Hedges’ g of the control group was 0.28. There was a significant within-subjects main 
effect across pre- and post-treatments, F(1, 33) = 22.32, p < .001, partial 2  = .403, and a 
significant main effect between treatment groups, F(1, 33) = 4.63, p = .039, partial 2  = .123. 
There was also a significant interaction between treatment group and time, F(1, 33) = 6.08, p = 
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.019, partial 2  = .156. Post hoc comparisons revealed a statistically significant difference 
between pre-treatment and post-treatment in the TeleCBT-I group only (p < .001). Figure 3 
exhibits the mean scores on dysfunctional beliefs about sleep by treatment groups from pre-
treatment to post-treatment.  
 
 
  
Figure 3. 
Scores on Dysfunctional Beliefs about Sleep by Group at Pre-treatment and Post-
treatment 
Note. Error bars represent 95% confidence intervals. 
***p < 0.001.  
 
 
Sleep Medication 
Patients in the TeleCBT-I group reported reduced use of sleep medication from pre-
treatment (52.63%, n = 10) to post-treatment (15.79%, n = 3).   
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Table 7. 
Scores on Sleep Measures by Group at Pre-treatment and Post-treatment and Treatment Effects  
 
 
 
    LMM Statistical Tests (Type III tests of fixed effects) 
 Pre-treatment Post-treatment  Time Effect Group Effect Group x Time Interaction 
 
Variables 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
g 
 
F(1, 33) 
 
p 
Partial 
2 
 
F(1, 33) 
 
p 
Partial 
2 
 
F(1, 33) 
 
p 
Partial 
2 
ISI               
    TeleCBT-I 17.79 3.57 7.58a*** 3.78 2.72 81.01 < .001 .711 6.80 .014 .171 28.29 < .001 .462 
    Control 17.50 4.71 14.88a* 5.82 0.48          
PSQI               
    TeleCBT-I 11.95 3.05 6 a*** 2.36 2.14 37.67 < .001 .533 5.65 .023 .146 24.70 < .001 .428 
   Control 11.69 3.96 11.06 4.06 0.15          
DBAS-16               
    TeleCBT-I 4.98 1.50 3.28 a*** 1.65 1.06 22.32 < .001 .403 4.63 .039 .123 6.08 .019 .156 
    Control 5.55 1.75 5.01 1.99 0.28          
Note.  TeleCBT-I (n = 19); Control (n = 16); Group effect sizes were computed as Hedges’ g values. 
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; ISI, insomnia severity inventory; PSQI, Pittsburgh sleep 
quality index; DBAS-16, dysfunctional beliefs about sleep. 
Means with subscript (a) are significantly different according to post hoc comparisons.   
*p < .05, **p < .01, ***p < .001. 
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Psychological Variables  
Fatigue 
As presented in Table 8, the TeleCBT-I group mean was reduced from pre-treatment (M 
= 4.60, SD = 1.62) to post-treatment (M = 3.01, SD = 2.48), reaching no clinically significant 
level of fatigue at post-treatment. However, the control group showed slightly increased levels of 
fatigue from pre-treatment (M = 4.89, SD = 2.44) to post-treatment (M = 5.27, SD = 2.09). 
Hedges’ g of the TeleCBT-I group was 0.74, while the Hedges’ g of the control group was 0.16. 
The results revealed only statistically significant Group x Time interaction on fatigue, F(1, 33) = 
10.21, p < .003, partial 2  = .236. Post hoc comparisons yielded a statistically significant 
difference between pre-treatment and post-treatment in the TeleCBT-I group only (p = .002).  
Depression   
The TeleCBT-I group reported similar scores from pre-treatment (M = 5.58, SD = 4.80) 
to post-treatment (M = 5.37, SD = 5.93) on depression. However, the control group reported 
slightly increased symptoms of depression from pre-treatment (M = 6.88, SD = 3.44) to post-
treatment (M = 7.13, SD = 4.23). Hedges’ g of the TeleCBT-I group was 0.04, while the Hedges’ 
g of the control group was -0.06. The effects of Time (p = .975), Group (p = .314), and Time x 
Group interaction (p = .711) were not significant on depression.  
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Anxiety  
Both treatment groups reported slightly reduced scores from pre-treatment to post-
treatment on anxiety. The HADS-Anxiety score decreased from 7.89 (SD = 4.22) to 6.53 (SD = 
3.22) in the TeleCBT-I group and from 8.44 (SD = 4.61) to 7 (SD = 4.27) in the control group. 
Hedges’ g of the TeleCBT-I group was 0.36, while the Hedges’ g of the control group was 0.32.   
Although no main effects were observed by Group (p = .95) and Group x Time interaction (p = 
.69), there was a statistically significant Time effect on anxiety, F(1, 33) = 5.90, p < .021, partial 
2  = .152. However, post hoc comparisons were not statistically significant for both treatment 
groups.  
Functional Assessment of Cancer Therapy 
Table 8 shows the mean and standard deviations of FACT-G and its subscales by 
treatment group. The FACT general and subscales scores were within the normal range of 
functioning in both treatment groups at pre-treatment and post-treatment. Nonetheless, the 
TeleCBT-I group resulted in slightly increased scores, while the control group reported slightly 
decreased scores from pre-treatment to post-treatment on the FACT general and all its subscales. 
Hedges’ g of the TeleCBT-I group for FACT general and all its subscales ranged from 0.24 to 
0.45, while for the control group ranged was from 0.04 to 0.30. Overall, no main effects were 
observed in the FACT general and its subscales, except for Group x Time interaction on FACT 
general, F(1, 33) = 6.4, p = .016, partial 2  = .162, physical well-being subscale, F(1, 33) = 8.20, 
p = .007, partial 2  = .199 and functional well-being subscale, F(1, 33) = 5.98, p = .020, partial 
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2  = .153. Post hoc comparisons resulted in statistically significant differences between pre-
treatment and post-treatment in the TeleCBT-I group for physical well-being (p = .017) and 
functional well-being (p = .051) subscales, while the control group revealed a statistically 
significant difference between pre-treatment and post-treatment only on the FACT general (p = 
.020). 
Quality of Life in Cancer Patients  
Table 9 shows the mean and standard deviations of QOL-CSV and its subscales by 
treatment group. A similar trend was found in quality of life as the TeleCBT-I group reported 
slightly improved quality of life from pre-treatment to post-treatment in QOL-CSV total and all 
its subscales. In contrast, the control group showed no changes on QOL-CVS total and its 
psychological and social subscales. Furthermore, the control group showed slightly decreased 
scores on QOL physical, but increased scores on QOL spiritual from pre-treatment to post-
treatment. Hedges’ g of the TeleCBT-I group for QOL-CVS Total and all its subscales ranged 
from 0.10 to 0.80, while for the control group ranged from was 0.01 to 0.36. No significant main 
and interaction effects were found on QOL-CVS total and all its subscales, except for the Group 
x Time interaction on QOL physical, F(1, 33) = 15.05, p < .001, partial 2  = .313. The same 
pattern was observed when analyses excluded one outlier for the QOL physical subscale. That is, 
the QOL physical subscale showed significant Time x Group interaction, F(1, 32) = 13.17, p  = 
.001, partial 2  = .292, but no main effects. Post hoc comparisons yielded a statistically 
significant difference between pre-treatment and post-treatment in the TeleCBT-I group for QOL 
physical subscale only (p = .001)  
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Table 8. 
Scores on Psychological Measures by Group at Pre-treatment and Post-treatment and Treatment Effects 
    LMM Statistical Tests (Type III tests of fixed effects) 
 Pre-treatment Post-treatment  Time Effect Group Effect Group x Time Interaction 
 
Variables 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
g 
 
F(1, 33) 
 
p 
Partial 
2    
 
F(1, 33) 
 
p 
Partial 
2    
 
F(1,33) 
 
p 
Partial 
2    
FSI               
   TeleCBT-I 4.60 1.62 3.01 a** 2.48 0.74 3.86 .058 .105 3.61 .066 .099 10.21 .003** .236 
   Control 4.89 2.44 5.27 2.09 0.16          
HADS-Depression               
   TeleCBT-I 5.58 4.80 5.37 5.94 0.04 .001 .975 .000 1.05 .314 .031 .140 .711 .004 
   Control 6.87 3.44 7.12 4.23 -0.06          
HADS-Anxiety               
   TeleCBT-I 7.89 4.22 6.53 3.22 0.36 5.90 .021* .152 .163 .689 .005 .004 .953 .000 
   Control 8.44 4.62 7 4.27 0.32          
FACT General               
   TeleCBT-I 71.37 19.21 79.58 22.04 0.39 .326 .572 .010 .799 .378 .024 6.4 .016* .162 
   Control 72.81 15.63 67.63 a* 17.85 0.30          
Physical well-being               
   TeleCBT-I 19.79 5.13 22.32 a* 6.29 0.43 .000 .988 .000 3.56 .068 .097 8.20 .007** .199 
   Control  18.88 4.87 16.38 7.27 0.06          
Social well-being               
   TeleCBT-I 18.42 6.68 20.05 6.85 0.24 .045 .833 .001 .004 .951 .000 1.34 .256 .039 
   Control 19.69 5.88 18.56 5.93 0.19          
Emotional well-being               
   TeleCBT-I 17.11 4.99 18.32 4.51 0.25 .732 .398 .022 .316 .578 .009 1.37 .251 .040 
   Control 17 4.32 16.81 4.35 0.04          
Functional well-being               
   TeleCBT-I 16 5.88 18.89 a* 6.56 0.45 .677 .417 .020 .256 .616 .008 5.98 .020* .153 
   Control 17.31 4.63 15.88 4.91 0.29          
Note. Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; FSI, fatigue symptom inventory; HADS-Depression, 
depression subscale of hospital anxiety and depression scale; HADS-Anxiety, anxiety subscale of hospital anxiety and depression scale; FACT, functional 
assessment of cancer therapy.  
Means with subscript (a) are significantly different according to post hoc comparisons; *p < .05, **p < .01. 
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Table 9. 
Scores on Quality of Life by Group at Pre-treatment and Post-treatment and Treatment Effects 
 
 
 
    LMM Statistical Tests (Type III tests of fixed effects) 
 Pre-treatment Post-treatment  Time Effect Group Effect Group x Time Interaction 
 
Variables 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
g 
 
F(1, 33) 
 
p 
Partial 
2    
 
F(1, 33) 
 
p 
Partial 
2    
 
F(1, 33) 
 
p 
Partial 
2    
QOL-CSV 
Total 
              
      TeleCBT-I 5.83 1.50 6.13 1.74 0.18 .232 .633 .007 .946 .338 .028 1.98 .169 .057 
     Control 5.59 1.42 5.44 1.12 0.11          
Physical               
      TeleCBT-I 6.23 1.64 7.47 a** 1.38 0.80 1.86 .182 .053 2.66 .112 .075 15.05 < .001*** .313 
     Control 6.30 1.81 5.70 1.95 0.31          
Psychological               
      TeleCBT-I 5.86 2.25 6.44 2.11 0.26 1.47 .234 .043 .316 .578 .009 1.54 .224 .045 
     Control 5.82 1.63 5.81 1.33 0.01          
Social               
      TeleCBT-I 6.09 1.82 6.37 2.15 0.14 .241 .627 .007 1.23 .276 .036 .341 .563 .010 
     Control 5.49 2.43 5.47 2.14 0.01          
Spiritual               
      TeleCBT-I 5.96 2.30 6.20 2.46 0.10 3.38 .075 .093 .372 .546 .011 .761 .389 .023 
     Control 6.16 2.02 6.84 1.65 0.36          
Note. Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia, QOL-CSV, quality of life-cancer survivor version. 
Means with subscript (a) are significantly different according to post hoc comparisons. 
Hedges’ g effect sizes were computed between pre-treatment and post-treatment scores by treatment group. 
*p < .05, ***p < .001. 
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Follow-Up Outcomes 
Sleep Variables 
  Patients in the TeleCBT-I group indicated that the improvements observed from pre- to 
post-treatment in all sleep variables were sustained at one-month follow. Table 10 presents the 
observed means for all three time points and treatment effects by treatment groups. Only the 
measures that demonstrated statistically significant Group (TeleCBT-I and Control) x Time (Pre-
treatment and Post-treatment) interactions were included in the follow-up analyses to assess 
differences between pre-treatment and follow-up and between post-treatment and follow-up. 
Insomnia Severity  
As shown in Figure 4, insomnia severity followed the same pattern as from pre-treatment 
to post-treatment. There was significant within-subjects main effect across the three time points, 
F(2, 58) = 73.20, p < .001, partial 2  = .716, and a significant main effect between treatment 
groups, F(1, 29) = 12.42, p = <.001, partial 2  = .300. There was also a significant interaction 
between treatment group and time, F(2, 58) = 23.04, p < .001, partial 2  = .443,  with post hoc 
tests revealing that there was a statistical significant difference in TeleCBT-I between pre-
treatment and follow-up (p < .001), but not between post-treatment and follow-up (p = .467). 
However, there was a statistically difference in the control group between pre-treatment and 
follow-up (p = .006) and post-treatment and follow-up (p = .043).   
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Figure 4. 
Scores on Insomnia Severity across the Three Time Points  
Note. Error bars represent 95% confidence intervals.  
* = p < .05 for significant difference between groups. 
† = p < .05 for significant main effect across times by treatment group.  
 
 
Sleep Quality  
Similarly, for sleep quality there was significant within-subjects main effect across the 
three time points, F(2, 58) = 32.10, p < .001, partial 2  = .525, and a significant main effect 
between treatment groups, F(1, 29) = 9.79, p = .004, partial 2  = .252. There was also a 
significant interaction between treatment group and time, F(2, 58) = 18.88, p < .001, partial 2  = 
.407,  with post hoc tests showing that there was a statistical significant difference in TeleCBT-I 
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between pre-treatment and follow-up (p < .001), but not between post-treatment and follow-up (p 
> .05). However, no statistically significance difference was found in the control group between 
pre-treatment and follow-up and between post-treatment and follow-up (ps > .05).  Figure 5 
presents the scores on sleep quality across all time points. 
 
 
  
Figure 5. 
Scores on Sleep Quality across the Three Time Points                                                                           
 
Note. Error bars represent 95% confidence intervals. 
* = p < .05 for significant difference between groups.  
† = p < .05 for significant main effect across times by treatment group.    
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Dysfunctional Beliefs about Sleep  
A similar pattern was observed in beliefs about sleep as in pre-treatment and post-
treatment comparisons. There was significant within-subjects main effect across the three time 
points, F(2, 58) = 13.77, p < .001, partial 2  = .322, and a significant main effect between 
treatment groups, F(1, 29) = 4.96, p = .034, partial 2  = .146. There was also a significant 
interaction between treatment group and time, F(2, 58) = 4.65, p = .013, partial 2  = .138,  with 
post hoc tests showing that there was a statistical significant difference in TeleCBT-I for beliefs 
about sleep between pre-treatment and follow-up (p = .002), but not between post-treatment and 
follow-up (p > .05). However, no statistically significance difference was found in the control 
group between pre-treatment and follow-up and between post-treatment and follow-up (ps > .05). 
Figure 6 presents the scores on dysfunctional beliefs about sleep across all time points.  
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Figure 6. 
Scores on Dysfunctional Beliefs about Sleep across the Three Time Points 
 
Note. Error bars represent 95% confidence intervals. 
* = p < .05 for significant difference between groups.  
† = p < .05 for significant main effect across times by treatment group.      
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Psychological Variables 
Fatigue  
Although no significant main effect between treatment groups (p = .109) was found, 
results shown a significant within-subjects main effect across the three time points, F(2, 58) = 
3.16, p = .05, partial 2  = .098 and a significant interaction between treatment group and time, 
F(2, 58) = 3.89, p = .026, partial 2  = .118. Post hoc tests showed that there was a statistical 
significant difference in the TeleCBT-I group for fatigue between pre-treatment and follow-up (p 
= .011), but not between post-treatment and follow-up (p > .05). However, no statistically 
significant difference was found in the control group between pre-treatment and follow-up and 
between post-treatment and follow-up (ps > .05). Figure 7 presents the scores on fatigue across 
all time points.  
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Figure 7. 
Scores on Fatigue across the Three Time Points 
 
Note. Error bars represent 95% confidence intervals.  
* = p < .05 for significant difference between groups.  
† = p < .05 for significant main effect across times by treatment group.      
 
FACT General Functioning and Physical Well-Being 
No statistically significant effects were observed for FACT general functioning and 
FACT physical well-being (ps > .05) at follow-up. However, FACT functional well-being 
showed statistically significant Group x Time interaction, F(2, 58) = 3.92, p = .025, partial 2  = 
.119), but no Time and Group main effects. Nonetheless, post hoc tests revealed a statistically 
significant difference between pre-treatment and follow-up in the TeleCBT-I group (p = .043). 
Figure 8 depicts the scores on functional well-being across all time points.  
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Figure 8. 
Scores on Functional Well-being across All Three Time Points  
 
Note. Error bars represent 95% confidence intervals.  
† = p < .05 for significant change from pre-treatment to post-treatment.      
 
 
Quality of Life Physical  
Although there was not a statistically significant within-subjects main effect across the 
three time points (p = .114), there was a significant main effect between treatment groups, F(1, 
29) = 4.38, p = .045, partial 2  = .131. There was also a significant Group x Time interaction, 
F(2, 58) = 14.24, p < .001, partial 2  = .329, with post hoc tests showing that there was a 
statistical significant difference in TeleCBT-I for physical QOL between pre-treatment and 
follow-up (p < .001), but not between post-treatment and follow-up (p = .794).  
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However, analyses conducted excluding one outlier revealed a slightly different pattern, 
as statistically significant differences were found for Time [F(2, 56) = 3.27, p = .045, partial 2  = 
.105], and Time x Group interaction [F(2, 56) = 12.30, p = .045, partial 2  = .105] effects, with 
similar results on post hoc tests showing statistical significant difference in TeleCBT-I for 
physical QOL between pre-treatment and follow-up (p < .043). Given the slight difference in 
results with and without outlier, analyses conducted without the outlier were interpreted. Figure 
9 presents the scores on physical quality of life across all time points.  
 
 
  
Figure 9. 
Scores on Physical Quality of Life across the Three Time Points 
 
Note. Error bars represent 95% confidence intervals.  
* = p < .05 for significant difference between groups. 
† = p < .05 for significant main effect across times by treatment group.        
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Table 10. 
Sleep and Psychological Scores by Group for All Time Points, Treatment Effects, Effect Sizes, and Post Hoc Results 
  
Means and Standard Deviations 
p values and Hedges’ g                           
in differences 
 
F- Tests 
 
  
Pre-treatment 
 
Post- treatment 
 
Follow- up 
Pre-treatment 
and Follow-up 
Post-treatment 
and Follow-up 
Time x Group 
Interaction 
Partial 
2 
Variables    p g p g   
ISI         
F(2, 58) = 23.04 
p < .001*** 
 
.443      TeleCBT-I 17.75 (3.84) 7.37 (3.68) 6.44 (4.53) < .001*** 2.7 .467 0.22 
     Control 17.73 (4.77) 15.60 (5.22) 13.87 (5.64) .006** 0.72 .043* 0.31 
PSQI         
F(2, 58) = 19.88 
p < .001*** 
 
.407     TeleCBT-I 12 (3.31) 6.06 (2.46) 4.94 (2.72) < .001*** 2.3 .163 0.43 
     Control 11.67 (4.10) 11 (4.19) 10.80 (4.16) .917 0.21 > .05 0.42 
DBAS-16         
F(2, 58) = 4.65 
p = .023* 
 
.138      TeleCBT-I 5.01 (1.60) 3.24 (1.78) 3.51 (1.93) .002** 0.84 .661 0.14 
     Control 5.53 (1.81) 4.90 (2.01) 5.35 (1.86) > .05 0.10 .169 0.23 
FSI          
F(2, 58) = 3.89 
p = .026* 
 
.118     TeleCBT-I 4.74 (1.74) 3.33 (2.56) 3.38 (2.05) .011* 0.71 > .05 0.02 
     Control 4.93 (2.52) 5.15 (2.10) 4.85 (2.04) > .05 0.03 > .05 0.14 
FACT General          
     TeleCBT-I 70.31 (20.30) 77.56 (23.44) 77 (21.80) .312 0.31 > .05 0.02 F(2, 58) = 2.52 
p = .103 
.080 
     Control 72.53 (16.13) 68.27 (18.28) 73.40 (17.77) > .05 0.05 .166 0.28  
Physical well-being          
     TeleCBT-I 19.31 (5.46) 21.75 (6.71) 21.56 (4.16) > .05 0.45 > .05 0.03 F(2, 58) = 2.84 
p = .067 
.089 
     Control 18.53 (4.84) 17.20 (6.70) 19.93 (5.23) > .05 0.27 .030 0.44  
Functional well-being          
     TeleCBT-I 15.44 (6.13) 18.06 (6.80) 18.75 (7.09) .043* 0.49 > .05 0.10 F(2, 58) = 3.92 
p = .036* 
.119 
     Control 17.07 (4.68) 15.87 (5.08) 16.07 (5.50) > .05 0.19 > .05 0.04  
QOL Physical          
     TeleCBT-I 6.25 (1.72) 7.48 (1.44) 7.73 (1.54) < .001*** 0.88 .789 0.16 F(2, 56) = .12.30 
p < .001*** 
.305 
     Control 6.52 (1.76) 6.21 (1.444) 5.99 (1.53) .359 0.31 > .05 0.14  
Note. Pre-treatment and post-treatment samples, TeleCBT-I (n = 19), Control (n = 16); Follow-up samples, TeleCBT-I (n = 16), Control (n = 15). 
Hedges’ g effect sizes were computed between pre-treatment and follow-up and between post-treatment and follow-up scores by treatment groups.  
Abbreviations:  TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia, ISI, insomnia severity inventory; PSQI, Pittsburgh sleep 
quality index; DBAS-16, dysfunctional beliefs about sleep; FSI, fatigue symptom inventory; FACT, functional assessment of cancer therapy; QOL-
CSV, quality of life-cancer survivor version. 
*p < .05, **p < .01, *** p < .001 
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Feasibility  
A total of 35 cancer patients (30 or 85.71% females) completed the study, indicating an 
overall 79.55% adherence rate for the entire sample. Two patients dropped out before initiating 
treatment and were considered lost to contact. Reason for discontinuation of the study is 
unknown for those lost to contact as they did not return outreach phone calls. During treatment, 
two patients dropped out, one due to medical complications related to cancer treatment (after 
session two), and one lost to contact (after session three). No adverse events were reported as a 
result of TeleCBT-I program. There were no statistically significant difference between dropouts 
and completers on insomnia severity and sleep quality as measured by ISI and PSQI (ps > .05).   
Out of the 21 patients who initiated TeleCBT-I treatment, 19 completed the four 
TeleCBT-I sessions, resulting in 90.48% adherence rate for the TeleCBT-I group. Booster 
sessions were offered and two patients completed an additional booster session within 1-2 weeks 
post-treatment. One-month follow-up was assessed based on the last treatment session or booster 
session. Most patients reported that telephone-delivery format was convenient (79%; M = 2.79, 
SD = .42). Additionally, more than half (n = 11, 57.89%) reported that they completed 
homework and treatment recommendations almost daily, while the rest (n = 8) daily.  
Patients reported high satisfaction with their overall TeleCBT-I program experience at 
post-treatment. Mean score for all nine items of the patient experience questionnaire was 2.73 
(SD = .36). The results for each item are presented in Figure 10. Overall, patients reported high 
satisfaction (M = 3.68, SD = .75) with the program. Additionally, most patients reported that they 
will likely recommend the TeleCBT-I to other cancer patients (M = 3.79, SD = .42). Out of 19 
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patients, 14 indicated the program manual was very helpful. Clinician’s performance was also 
rated highly (M = 2.73, SD = .36). 
 
 
 
Figure 10. 
Patient Reported Overall Experience and Satisfaction with TeleCBT-I  
 
 
Qualitative questions yielded specific recommendations for the TeleCBT-I program. 
Overall, patients favored educational information of healthy sleep and how sleep is related to 
cancer, as well as, gaining self-awareness of sleep patterns (n = 9, 47.37%; e.g. “I learned a lot! 
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It changed my way of doing things and I told all my family”, “It gave me more awareness of my 
sleep problems”, “Realizing that sleep was important for cancer treatment, no other provider 
mentioned that to me”), sleep hygiene (n = 7; 36.84%; “Tips on preparing to go to sleep, sleep 
hygiene”) and the combination of behavioral and cognitive techniques (n = 14, 73.68%; 
“Different strategies to overcome negative sleep thoughts, [and] like covering my clock, it was a 
secret weapon!”). 
Although, a sizeable number of patients reported no improvements needed (n = 8, 
42.11%; “All positive, life saver!”, the majority provided specific recommendations to improve 
TeleCBT-I. Recommendations included reducing the overall amount of information and 
strategies as the program was potentially a source of additional anxiety (n =1), and improve the 
relaxation log as it was confusing (n =1). Patients also identified aspects of the program that they 
disliked, such as: Stimulus control (n = 2), sleep restriction (n = 1), sleep medication information 
(n = 1), and relaxation techniques (n =1). Additional recommendations included: To extend 
TeleCBT-I from four to six sessions (n =1), to include more relaxation techniques (n =1), and to 
offer CBT-I sooner, or right after a cancer diagnosis (n = 2). 
These results underscore patients’ overall high satisfaction with TeleCBT-I, and pointed 
three valuable recommendations: (1) to extend the TeleCBT-I to spread-out the information and 
allow more time to learn and practice the behavioral, cognitive and relaxation techniques, (2) to 
improve the self-monitoring logs by making them more user-friendly, and (3) to increase access 
to CBT-I by increasing dissemination efforts from the time of cancer diagnosis and throughout 
the cancer care continuum.     
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Intent to Treat Results  
Intent to treat analyses were conducted using the full analysis set, which includes two 
patients that dropped out the study after completing pre-treatment measures and two patients 
who did not complete treatment. The last observation carried forward imputation method was 
used to assign post-treatment values. The tables presented in Appendix K detail the ITT results.  
Overall, per protocol analysis produced similar findings as the intention-to-treat analysis, 
increasing the confidence in the study results (Moher et al., 2010). As observed in the main 
results as per-protocol, there were no differences between treatment groups on any of the 
demographic and cancer related information at pre-treatment, except for personal income (p = 
.042). Similarly, no differences were found on sleep and psychological measures at pre-treatment 
between the TeleCBT-I and Control groups (ps >.05). 
Although the results from the repeated measures analyses of variance followed the same 
pattern as the per-protocol results, two differences were found. The Group effect on 
dysfunctional beliefs about seep (DBAS-16) was found not statistically significant as per ITT 
analyses, F(1, 37) = 2.56, p = .118, partial 2  = .065, while functional physical well-being 
reached statistically significant values, F(1, 37) = 4.57, p = .039, partial 2  = .110.  
Feasibility analyses were not computed because this was only assessed at post-treatment. 
In sum, the ITT analyses revealed similar patterns as the as per-protocol analyses. Thus, ITT 
results demonstrated that the per-protocol results represent unbiased treatment effects.  
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CHAPTER FIVE: DISCUSSION 
The current study tested the efficacy and feasibility of a brief telephone-delivered CBT-I 
program for the treatment of insomnia in cancer patients compared to a treatment-as-usual 
control group. The main study hypotheses that patients in the TeleCBT-I group compared to 
control would report beneficial changes in all sleep variables immediately after treatment and 
that these changes would be maintained at one-month follow-up were supported.  
Patients in the TeleCBT-I group reported reduced insomnia severity, improved sleep 
quality and decreased dysfunctional sleep beliefs at post-treatment and one-month follow-up. 
Additionally, most patients in the TeleCBT-I group discontinued sleep medications at post-
treatment, increasing the potential of experiencing less side effects and incurring in additional 
treatment costs. These findings are consistent with prior research supporting the effectiveness of 
CBT-I in patients with cancer compared to a treatment-as-usual control group (Bastien et al., 
2004; Espie et al., 2008). Indeed, the magnitude of effects found at post-treatment for TeleCBT-I 
are comparable to those found in a recent meta-analysis for insomnia severity score (ISI) 
(Johnson et al., 2016). Further, these findings are also similar to studies examining CBT-I in 
cancer populations, providing further evidence of the effectiveness of CBT-I in cancer patients 
(Casault et al., 2015; Dirksen & Epstein, 2008; Espie et al., 2008; Matthews et al., 2014; Zhou, 
Partridge, Syrjala, Michaud, & Recklitis, 2017) 
The hypothesis that TeleCBT-I would also have positive effects on fatigue, depression, 
anxiety, functioning, and quality of life was partially supported. Although patients in the 
TeleCBT-I group indicated greater improvements in fatigue compared to control at post-
treatment, there were no time and group effects. However, results showed a statistically 
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significant interaction effect at post-treatment and follow-up, indicating significant differences 
between treatment groups and over time on fatigue. Further, patients in the TeleCBT-I group 
reported lower scores and reached subclinical levels at post-treatment, while patients in the 
control group reported slightly higher and clinical levels of fatigue at post-treatment.  
Among cancer patients, fatigue is one of the most common complaints resulting from 
cancer treatment (Donovan, Jacobsen, Small, Munster, & Andrykowski, 2008). However, its 
presence and impairment are highly influenced by the course and type of cancer treatment that 
patients undergone. It is possible that fatigue may stay constant during the course of cancer 
treatment, and TeleCBT-I treatment improved patients’ ability to cope with fatigue over time. 
Thus, improved perceived sleep quality and overall sleep, may increase a person’s ability to cope 
with fatigue. Alternatively, changes in cancer treatments and recurrence in cancer symptoms may 
dilute TeleCBT-I treatment effect as this study did not exclude patients based on type or current 
cancer treatment. And therefore, patients could have experienced changes during the course of 
TeleCBT-I treatment. Nonetheless, the impact of CBT-I on fatigue in this study was similar as 
found in previous studies with cancer patients (Dirksen & Epstein, 2008; Heckler et al., 2016; 
Johnson et al., 2016). However, more research is needed to determine what aspects of CBT-I 
better target fatigue in cancer patients. 
Importantly, both treatment groups reported normal to subclinical symptoms of anxiety 
and depression at pre-treatment. As a result, this study was unable to examine whether TeleCBT-
I is also helpful to address anxiety and depressive symptoms. Nonetheless, while depressive 
symptoms remain the same in the TeleCBT-I group, a slight reduction of anxiety symptoms was 
observed at post-treatment in both treatment groups, suggesting that TeleCBT-I does not produce 
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negative effects on anxiety and depression. Alternatively, it is possible that TeleCBT-I has no 
effect on anxiety and depressive symptoms in cancer patients, and thus, the reduction of 
symptoms may be an artifact of the natural decline often observed in mental health symptoms. 
Previous research provide mixed evidence on the impact of CBT-I in other psychological 
variables, such as fatigue, anxiety and depression (Quesnel et al., 2003; Savard et al., 2016; 
Tremblay et al., 2009). This study provides further support of the need to investigate which 
aspects of CBT-I address anxiety and depressive symptoms and whether the same aspects apply 
to cancer patients.  
Moreover, patients in the TeleCBT-I showed significant improvements in general 
functioning, physical well-being, functional well-being, and physical quality of life compared to 
those in the control group at post-treatment. However, treatment gains were only sustained at 
one-month follow-up in the functional subscale of general functioning and the physical subscale 
of quality of life. Importantly, these findings suggest that TeleCBT-I has a positive effect on 
daily functioning and physical quality of life in patients with cancer whose daily functioning and 
physical health is often significantly deteriorated during and after cancer treatment. Thus, these 
findings suggest the CBT-I may be beneficial to cancer patients as improvement in sleep may 
result in improvements in other aspects of physical health.  
Overall, post hoc analyses revealed substantial changes across all time points. As 
expected, patients in the TeleCBT-I group demonstrated significant changes from pre-treatment 
to follow-up, but not from post-treatment to follow-up in all sleep measures. A further 
examination of the means indicated that these changes were all indicative of reduction of 
insomnia symptoms. Effect sizes (Hedges’ g) between pre-treatment and follow-up were all large 
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(.84 – 2.7). These results suggest that TeleCBT-I is a viable option for treating insomnia in 
cancer patients. Additionally, patients in the TeleCBT-I group reported statistically significant 
improvement in fatigue, functional well-being, and physical QOL from pre-treatment to follow-
up, suggesting that TeleCBT-I contributed to improvements in their perception of physical health 
and daily functioning.  
As expected the control group showed no significant changes from pre-treatment to 
follow-up and from post-treatment to follow-up on all sleep and psychological measures, except 
for insomnia severity and physical well-being. That is, a statistically significant decline was 
observed in insomnia severity from pre-treatment to follow-up and from post-treatment and 
follow-up in the control group. In terms of physical well-being, only the increase of scores from 
post-treatment to follow-up was statistically significant. It is possible that these results in the 
control group are attributable to the typical improvement observed in mental health symptoms 
over time.   
In terms of feasibility, previous research using telehealth modalities, provide encouraging 
evidence to further examine whether telephone calls, which are an inexpensive means of 
communication, can be used to provide evidence-based interventions, such as CBT-I. Indeed, 
this study demonstrated that telephone-delivered CBT-I produces similar improvements in 
insomnia symptoms as face to face delivered modalities. Overall, patient adherence was high 
(90%) and most patients completed all required treatment sessions. Additionally, patients 
reported high satisfaction with TeleCBT-I and indicated that they would highly recommend it to 
other cancer patients. Together, these results indicate the telephone-delivered CBT-I is not only 
effective at reducing insomnia symptoms, but also feasible in patients with cancer.     
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Strengths  
Based on the existing literature, this is the first study that tests telephone-delivered CBT-I 
in a sample of patients with cancer. A major strength of this study was the randomized controlled 
design that followed the CONSORT guidelines (Moher et al., 2010) and compared the treatment 
group to a control group. Further, this study attempted to reflect the reality of clinical practice by 
using a limited exclusion criterion and therefore allowing patients with different types of 
diagnoses and stages of cancer to participate in the study. Additionally, patients were allowed in 
the study regardless of the cancer treatment they were undergoing. Current sleep medication was 
also allowed as many patients with cancer are prescribed sleep medication during cancer 
treatment. Another strength was the use of well-defined diagnostic criteria.  
Although the main goal of the study was to test the use of telephone communication as a 
platform to provide CBT-I, patients were required to complete an in-person diagnostic interview 
to assess current insomnia symptoms and other co-morbid mental health conditions. The newly 
developed DSM-5 sleep module was used to determine insomnia diagnosis based on the DSM-5 
criteria. Outcome measures were selected based on existing recommendations for insomnia 
research facilitating future replication and comparison of results with previous research. Another 
strength of the study is the use of an adapted CBT-I multicomponent program making it more 
relevant to the study population. Lastly, treatment and assessments were conducted over the 
telephone extending the use of telehealth to data collection practices and providing patients with 
a consistent platform throughout their involvement in the study. 
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Limitations  
Although the innovative aspects of this study advance the evidence of CBT-I and its 
dissemination and implementation via telephone-delivery in a sample of cancer patients, the 
most notable limitation is the small sample size. Although sample size satisfied the minimal size 
requirement for the purpose of this study, future research should involve larger sample sizes in 
order to increase the statistical confidence of the results. Further, although the study included a 
wide range of cancer diagnoses, the small sample limited the ability to examine group 
differences based on type of cancer diagnosis and other variables of interest, such as age, 
race/ethnicity, cancer stage, and use of sleep medications. Additionally, some of the measures 
indicated a low reliability, which could be an effect of the combination of small sample size and 
small number of items.  
In terms of sleep indicators, the study did not assess sleep onset latency, total sleep time, 
time awake after sleep onset, sleep efficiency and number of awakenings throughout the course 
of TeleCBT-I and across all time points. These measures provide a more detailed 
characterization of sleep patterns. Additionally, no objective sleep measures were used in the 
study. Although insomnia is diagnosed based on patients’ perception of their sleep disturbance, 
daytime symptoms, and impairment in daily functioning, actigraphy and polysomnography 
identify other sleep problems (e.g., sleep apnea) that may be causing the underline sleep 
disturbance. Thus, this study is unable to confidently assert that the sample had only diagnosable 
insomnia with no presence of other sleep condition.  
Treatment integrity as provided by three different clinicians was not assessed. However, 
clinicians were supervised by a licensed clinical psychologist and followed a manualized 
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program. In addition, patients received the same TeleCBT-I workbook, which provided 
instructions and information that guided each session. Nonetheless, larger trials would benefit 
from including fidelity measures.  
The control group was deemed as treatment-as-usual, instead of a wait-list control group 
because patients and providers were allowed to make changes to sleep medications throughout 
the course of the study. Typically, wait-list control group are not offered or allowed any 
treatment associated with the researched treatment. Thus, it is possible that patients in the control 
group were actively using sleep medications or initiated or discontinued their sleep medication 
during the course of the study making significant changes in their perception of sleep problems. 
However, the study did assess for engagement in non-pharmacological treatments for insomnia 
at post-treatment and follow-up and this was considered a reason for discontinuation in the study.  
Although the study provides evidence for sustained effects on insomnia improvement at 
one-month follow-up, future research investigating the effects of TeleCBT-I in cancer patients 
over extended periods of time are needed. Lastly, the findings of this study are not generalizable, 
but provide preliminary evidence for the efficacy and feasibly of using telephone calls to provide 
a brief program of CBT-I in patients with cancer. Although the TeleCBT-I group reported 
significant and sustained improvements in their sleep, more research is needed to understand 
among patients with cancer, who does and does not benefit from CBT-I delivered via telehealth 
platforms.  
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Conclusion  
Insomnia can be treated successfully in cancer patients using telephone-delivered CBT-I. 
The four-week CBT-I program adapted for cancer patients led to decreased insomnia severity, 
improved sleep quality and reduced dysfunctional thoughts about sleep in patients with cancer 
with sustained gains observed at one-month follow-up. TeleCBT-I may have a positive impact 
on fatigue, anxiety, functioning and quality of life, but more research is needed. Lastly, 
telephone-delivered CBT-I is feasible and highly accepted among cancer patients.    
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Sleeping Well Study: Evaluating Format Efficacy for Cognitive-Behavioral 
Therapy for Insomnia in Adult Cancer Patients 
 
Sleep Problems among Cancer Patients  
 Sleep disturbances are among the most common and distressing symptoms endorsed by 
cancer patients. 
 Up to 80% of cancer patients experience sleep disturbances, while up to 60% suffer from 
insomnia. 
 The 2016 guidelines of the National Comprehensive Cancer Network (NCCN) and the 
American College of Physicians (ACP) recommend the screening and assessment of sleep 
complaints and treatment of insomnia during routine cancer care. 
 The NCCN and ACP recommend that all adult patients with cancer and comorbid insomnia 
symptoms receive Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first line of 
treatment. 
 
Challenges to Providing CBT-I to Cancer Patients 
 Insomnia is often untreated and when treatment is offered, it generally entails medication 
only. 
 CBT-I is under-utilized and under-researched in cancer populations. 
 Barriers include a lack of trained providers, commute to treatment centers, and treatment 
duration. 
 
The Sleeping Well Study will address these challenges by providing a brief CBT-I intervention 
tailored to cancer patients via telephone! Participants will be randomized to either one of three 
groups: (1) individual telephone sessions, (2) group telephone sessions or (3) a wait-list control 
group. The CBT-I intervention consists of 3-4 sessions delivered 1 per week and over 1 month 
period. Participants will also be followed at 3 and 6-month after treatment.  
 
For more information, please contact Andel Nicasio at 321-841-5056/Andel.Nicasio@orlandohealth.com 
 
.   
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Sleeping Well: Telephone Script 
 
Phone Script for Screening for Leaving Voicemail #1  
This message is for ____. This is ____ from the Cancer Support Community at Orlando 
Health. I’m calling to tell you about our Sleeping Well research study we are running here at the 
center. The study will be evaluating a brief talk therapy program tailored for adult cancer patients 
experiencing sleep problems. This form of talk therapy, called CBT, is the recommended 
treatment for sleep problems, but can also help reduce fatigue, anxiety and depression, and 
improve overall quality of life. It only requires one in-person visit with the rest of the study 
completed over the phone. We are currently seeking participants, so if you’d like to learn more 
about this study, please give us a call back at 321.841.5056. Thank you and have a great day. 
 
Phone Script for Screening for Leaving Voicemail #2 
This message is for ____. This is ____ from the Cancer Support Community at Orlando 
Health. I’m calling to find out if you might be interested in participating in a study evaluating a 
brief talk therapy program tailored for adult cancer patients experiencing sleep problems. This 
study is conducted over the phone and only requires one in-person visit to get started. If you’d 
like to learn more about this study, please give us a call back at 321.841.5056. Thank you and 
have a great day. 
 
Phone Script for Screening for Leaving Voicemail #3 
This message is for ____. This is ____ from the Cancer Support Community at Orlando 
Health. The reason for my call is to tell you about a Sleeping Well study we are conducting 
where we will be providing a brief talk therapy program for sleep problems in adult cancer 
patients. This study only requires one in-person visit with the rest completed over the phone. 
This is the final phone call to you regarding this study, so if you are interested in learning 
more about it, please give us a call back at 321.841.5056. Thank you and have a great day. 
 
Phone script for Live Call 
Hi. Is this ___? My name is ___ and I’m calling from the Cancer Support Community at 
Orlando Health. How are you today? [open response]. I’m calling today to tell you about our 
Sleeping Well Study that we’re conducting through the center and I wanted to find out if you’d 
be interested in possibly participating.  
 
[If No] – Ok. Just to let you know, the Cancer Support Community offers a variety of 
free support including mindfulness workshops, yoga, art & crafts, and support groups. We invite 
you to stop by and say hello.  
 
[If Yes] OK Great, so this study will be using talk therapy tailored for cancer patients to 
help reduce sleep problems. We will be using Cognitive-Behavioral Therapy, also called CBT 
which is a form of talk therapy that has been recommended for treating sleep problems, 
particularly insomnia but it can also help with fatigue, anxiety, depression, and overall quality of 
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life. Basically, we will be evaluating the effectiveness of CBT treatments provided over the 
phone.  
The study starts with a brief phone screening to see if you qualify. If you qualify, we will 
set up your in-person interview where we further evaluate sleep problems and any other 
emotional issues. You’ll only need to attend this one interview as the rest can be completed over 
the phone. You will be randomly assigned to one of three groups. Group 1 will receive individual 
treatments over the phone; Group 2 will receive CBT-I treatments in a group conference call 
format; and group 3 will be waitlisted but given the option to receive CBT-I treatment over the 
phone or in person. The study includes 3 to 4 phone therapy sessions and a 1, 3, and 6 month 
follow-up phone call interview, each lasting approximately 1 hour.  
 
Participation is completely voluntary and at no cost to you. Your participation in this 
study will not affect your current treatment at UF Health Cancer Center - Orlando Health. Do 
you have any questions about the study?  
 
Would you be interested in participating in this study? 
- If Yes… Proceed with the screening information. 
- If No… Thank Her/Him for her/his time. End of contact. 
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Sleeping Well Study: Telephone Screening 
 
1. Are you 18 years old or older? 
If Yes… Continue. | If No… Discontinue.  
 
2. Are you a cancer patient? 
(Cancer patient could be any one with a diagnosis of cancer stages I-IV and who 
is receiving treatment or has recently completed treatment (< less than 5 years after 
completing treatment or that the person is in complete remission) 
If Yes… Continue. | If No… Discontinue.  
 
3. Are you a patient at Orlando Health UF Health Cancer Center? 
If Yes… Continue. | If No… Discontinue.  
 
4. Do you currently have trouble sleeping? 
If Yes… Continue. | If No… Discontinue.  
 
5. Have you ever been diagnosed with Sleep apnea? 
If Yes… Ask if S/He is currently receiving treatment for Sleep Apnea. 
- If Yes, continue. | - If No… Discontinue.  
If No… Continue. 
 
6.  Have you ever been diagnosed with Restless Legs Syndrome (RLS)? 
If Yes… Ask if S/He has a current diagnosis of RLS and if S/He is currently 
receiving treatment for RLS. 
- If Yes for either question above … Discontinue.  
If No… Continue. 
 
7. Have you been diagnosed with Periodic Limb Movement Disorder (PLMD)? 
If Yes… Ask if S/He has a current diagnosis of PLMD and if S/He is currently 
receiving treatment for PLMD. 
- If Yes for either question above… Discontinue.  
If No… Continue. 
 
8. Have you been diagnosed with Narcolepsy? 
If Yes… Ask if S/He has a current diagnosis of Narcolepsy and if S/He is 
currently receiving treatment for Narcolepsy. 
- If Yes to either question above … Discontinue.  
If No… Continue. 
 
9. Are you able to attend an interview session at UF Health Cancer Center-Orlando 
Health, Integrative Medicine Department?  
If Yes… Continue. | If No… Discontinue.  
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10. Are you able to attend 3-4 sessions, one per week, over the telephone?  
If Yes… Continue. | If No… Discontinue.  
Okay. Thanks for answering these questions. Now, I am going to ask you more specific 
questions about your sleep. We are almost done with the phone screening.  
 
 
SQD Administration  
 
 QUALIFIES IF: Score of 3, 4 or 5 in any questions indicates possible insomnia or sleep 
problems.  
We’ve finished the screening now, and you qualify for the study. The next step is to 
schedule the appointment for the in-person interview. This interview will further evaluate 
your eligibility and ask more questions about your sleep and potential emotional problems. 
You will also be assigned to one of the 2 groups.  
 
Schedule Intake Appointment (in-person). Thank Her/Him for their time and 
provide the Cancer Support Community telephone number (321-841-5056) to call back if 
S/He has any questions. 
 
 DOES NOT QUALIFY IF: Scores of 1-2 in all questions. Discontinue.  Explain 
participant that S/He is not eligible for this study, but that S/He is welcome to enroll in 
other studies at UF Health Cancer Center-Orlando Health for which S/He qualifies in the 
future. Thank Her/Him for her/his time.  
 
 
 
 
 
 
 
  
96 
 
APPENDIX F: PROCEDURES FLOW CHARTS 
97 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
 
 
 
 
 
 
 
99 
 
 
100 
 
 
 
101 
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Sleeping Well Study 
Sleep and Demographic Information  
 
All information on this sheet is strictly confidential.  
 
Date: _______________ 
 
Contact Information:  
Last Name: ______________________ First Name: ___________________ Middle Initial: ____ 
Address: ______________________________________________________________________ 
Phone: ___________________________ Is it Okay to leave voice messages?  Yes      No 
Email: __________________________________________   
 
Emergency Contact: ___________________________ Phone Number: ____________________ 
Relationship to Emergency Contact: ________________________________________________   
 
Referring Physician or Medical Provider: _______________________________________ 
 
 
Sleep Information 
What is your main sleep complaint? ____________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
Past Sleep Evaluation and/or Treatment:  
 I have had a previous sleep disorder evaluation  
 I have been prescribed PAP for home use  
 I wear oxygen at night  
 I have had a previous overnight sleep study  
 I have had surgical treatment for a sleep disorder  
 I have a family member with sleep apnea  
 
Please list  
1) Date of Prior Sleep Study: _______________ 
2) Diagnosis: ____________________________ 
3) Treatment if applicable: ____________________________ 
 
Duration of Symptoms: _______________months / years 
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Have you received any treatment for sleep problems?  
 Yes      No  
If yes, please indicate below: 
 Medication  
 Relaxation techniques  
 Psychotherapy  
Other. Please describe: __________________________________________________________ 
 
 
Sleep Habits 
 I usually watch TV in bed prior to sleep  
 I usually read in bed prior to sleep  
 I eat a snack at bedtime  
 I work a rotating shift or I am a shift worker  
 I smoke prior to bedtime or when I awaken during the night  
 I eat if I wake up during the night  
 I often travel across two (2) or more time zones  
 I drink alcohol in the evening time to help get to / stay asleep  
 
 
Bedroom Habits 
 I sleep alone  
 I share a bed with someone  
 I share a dwelling but have separate bedrooms  
 I share the bed with pets  
 I have an uncomfortable bed or pillow  
 I have an uncomfortable temperature in the bedroom  
 I have a noisy bedroom or have too much light in the bedroom  
 I have too many electrical devices in the bedroom  
 
 
Sleep Pattern: 
Typical bedtime ______________________ AM/PM  
How many minutes to fall asleep _________________________ 
How many awakenings in the night? _____________  
Do you fall back to sleep easily? Yes   No   
Typical wake-up time ________________ AM/PM  
Do you nap? Yes     No      If yes, when / how long _______________ 
 
Other relevant Information about Sleep:  
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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Cancer Diagnosis Information 
With which type of cancer were you diagnosed? 
 Breast cancer  
 Lung cancer  
 Non-Melanoma skin cancer  
 Melanoma skin cancer  
 Prostate cancer  
 Bladder cancer  
 Colon cancer  
 Pharyngeal (Throat cancer)  
 Melanoma  
 Non-Hodgkin’s Lymphoma  
 Thyroid cancer  
 Kidney cancer (renal cell)  
 Leukemia  
 Pancreatic cancer  
 Endometrial cancer  
 
 Other  Please specify: _________________________________________________________ 
 
How long ago were you diagnosed with cancer? 
 Less than 1 year ago  
 1 year ago to 2 years ago  
 2 years to 5 years ago  
 _____________________ Include date if known or provided 
 
At what stage were diagnosed? 
 Stage I  
 Stage II  
 Stage III  
 Stage IV  
 Limited Stage  
 Extensive Stage  
 
Which of the following best describes your current condition? 
 My stage has remained the same  
 My stage has increased   
 I am cancer free  
 
Have you ever undergone any of the following cancer treatments to help reduce or control 
the spread of your cancer? (Check all that apply) 
 Chemotherapy  
 Radiation therapy  
 Hormonal therapy  
 Surgery  
 Targeted drug therapy (Treatment targets changes in cancer cells)  
 Stem cell transplant  
 Clinical trial  
 I have not undergone any cancer treatments  
 Other. Please specify: _________________________________________________________ 
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What type of cancer treatment are you currently receiving? (Check all that apply / See 
Next Page) 
 Chemotherapy  
 Radiation therapy  
 Hormonal therapy  
 Surgery  
 Targeted drug therapy (Treatment targets changes in cancer cells)  
 Stem cell transplant  
 Clinical trial  
 No cancer treatment at this time  
 Other. Please specify: _________________________________________________________ 
 
 
When do you expect to complete your current cancer treatment? (If applicable) 
______________________________________________________________________________ 
 
 
Are you using any other healing methods? Please check all that apply 
 Acupuncture      Massage Therapy  
 Chiropractor      Medical Doctor  
 Energy Healing      Mental Health Professional  
 Physical Therapist      Music or Art Therapy  
 Other. Please describe: _______________________________ 
 
Mental Health History 
Have you ever been diagnosed with a mental illness?  
Yes     No  
If yes, please indicate diagnosis: ___________________________________________________ 
 
Have you ever been hospitalized in relation to mental health?  
Yes      No  
If yes, please describe: ___________________________________________________________ 
 
Pain 
On a scale of 0 (no pain) to 10 (extreme pain),  
A. What is your level of pain right now? ________ 
B. What has your average pain level been over the past month? _________ 
 
Have you had a recent surgery (within the past 6 months) 
Yes      No  
If yes, please describe: ___________________________________________________________ 
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Caffeine intake 
Do you consume caffeine?       Yes     No  
If Yes, do you consume    Coffee           Caffeinated drinks            Caffeine pills  
 
Estimate average cups of coffee per day? _________________ Oz/ Cups 
On a typical day, when do you drink coffee? 
 Morning (6am-noon)         Afternoon (noon-6pm)      Evening 6pm-2am)        Night 
(2am-6am)  
 
Sodas, tea, Jolt®, Mountain Dew®, Red Bull ®, Monster®, ROCKSTAR Energy Drinks® 
Estimate average number of caffeinated drinks per day? _________________ Oz/ Drinks 
On a typical day, when do you drink caffeinated drinks? 
 Morning (6am-noon)        Afternoon (noon-6pm)       Evening 6pm-2am)       Night 
(2am-6am)  
  
Tobacco Intake 
Have your ever smoked?  
 Yes      No  
 
If Yes, how long have you smoked?  ___________ Years 
How much? _________________Number of cigarettes/Day  (1 pack has 20 cigarettes; Export As 
has 25) 
 
Have you quit smoking? 
 Yes      No  
If Yes, Year Quit __________________ 
If No, do you use cigarettes, smokeless tobacco, snuff, or other tobacco products? 
__________________________________________________________________ 
How much per day? __________________________ 
 
Alcohol Intake 
Do you drink Alcohol? 
 Yes      No   
If Yes, how much do you drink? ___________ drinks  
How frequent?       Daily     Weekly (_______times per week)    Socially ______________ 
What kind of alcohol?   Beer   Liquor   Wine  
Do you drink alcohol before going to bed frequently?       Yes      No  
 
Do you use any other substances?    Marijuana    Cocaine     Crack     Other: ________ 
Do you use of these substances to help fall asleep or take it before going to bed?  Yes    No  
 
Exercise 
Do you exercise?          Yes     No  
If Yes, how frequently? _________________________________ 
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Other Health History 
Have you been diagnosed with a chronic or severe health condition? Please check all that 
apply. 
    
 Asthma       
 Back Pain    
 Arthritis     
 Chronic fatigue syndrome    
 Diabetes   
 Multiple Sclerosis  
 Heart Condition  
 High/Low Blood Pressure  
 Headaches/Migraine   
 Eating Disorders  
 ADHD       
 Anxiety       
 Bipolar Disorder      
 Depression       
 Panic attacks      
 PTSD       
 Schizophrenia      
 Other, please specify: _________________________ 
 
Current Medication 
Please list all your current medications 
 
Prescription Medication Name How much? How often? Last taken? 
    
    
    
    
    
    
    
    
    
    
    
    
Over-the-counter Medication Name How much? How often? Last taken? 
    
    
    
    
    
    
Herbal Remedy / Nutritional 
Supplement Name 
How much? How often? Last taken? 
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General Demographic Information 
 
Age: _______ DOB: _______________      
 
Gender:      
 Female       Male     Other. Please specify: _________________________ 
 
What is your height? ___________ Feet ________Inches 
What is your weight today? ________  Weight one year ago? ________ 
 
Marital Status:  
 Married     Single    Divorced      Life Partner  Separated  Widowed  
 Other. Please specify: ________________________________ 
 
Race/Ethnicity: 
 Asian/Pacific Islander  
 Black or African American  
 Hispanic or Latino  
 Middle Eastern (Arabs, Turks, Persians, Jews, etc.)  
 Native American or Alaska Native  
 South Asian (India, Pakistan, Bangladesh, Nepal, etc.)  
 White 
 Other. Please specify: ____________________________ 
 
Employment Status 
 Active Duty Military  
 Disabled  
 Employed Full-Time  
 Employed Part-Time  
 Homemaker  
 
 Not Employed  
 Retired  
 Self Employed  
 Student Full-Time  
 Student Part-Time  
 Other. Please specify: _________________ 
 
Highest Level of Education 
 No schooling completed  
 Some school, but less than 8th grade  
 Completed 8th grade  
 Some high school, no diploma  
 High school graduate, diploma or the equivalent of GED  
 Some college, no degree  
 Trade/technical school/vocational training  
 Associate degree  
 Bachelor’s degree  
 Master’s degree  
 Professional degree  
 Doctorate degree  
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Personal Annual Income    Household Annual Income  
 Less than $15,000      Less than $15,000  
 $15,000 – $24, 999     $15,000 – $24, 999  
 $25,000 – $34,999      $25,000 – $34,999  
 $35,000 – $49,999      $35,000 – $49,999  
 $50,000 – $74, 999     $50,000 – $74, 999  
 $75,000 or more      $75,000 or more  
 Does not apply  
 
Religious Preference 
 Atheism/Agnosticism  
 Buddhism  
 Catholicism  
 Christianity 
 Hinduism  
 Judaism   
 Mormonism  
 Islam  
 Orthodox Church such as Greek or Russian Orthodox Church  
 Protestantism  
 Seventh-Day Adventists  
Other. Please specify: _____________________________________________ 
 
 
For Research Personnel Only 
Referral Date: ______________ By: _________________________ 
Med approval date: ___________________ 
Eligible: (Y/N): _____________________  Exclusion reason (if applicable): ________________ 
Consented: (Y/N): ______________________ Date: __________________ 
Randomization group: ___________________ 
Screening Date: ___________________  
Baseline date: ____________________  
Sleep Diary Start Date: _______________ 
Session 1: Date: ___________ Attendance (Y/N): _______  
Session 2: Date: ___________ Attendance (Y/N): _______ 
Session 3: Date: ___________ Attendance (Y/N): _______ 
Session 4: Date: ___________ Attendance (Y/N): _______ 
Post-Assessment Date (scheduled): _________________  Completion date: ________________ 
1 MONTH FU Date (scheduled): ___________________ Completion date: ________________   
3 MONTH FU Date (scheduled): ___________________ Completion date: ________________ 
6 MONTH FU Date (scheduled): ___________________ Completion date: ________________ 
Lost to contact: (Y/N): ______ Date of last contact: _____________________ 
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Research Study:  
Sleeping Well: Evaluating Format Efficacy for                                                           
Cognitive-Behavioral Therapy for Insomnia in Adult Cancer Patients 
 
Request for Release to Participate 
 
Orlando Health | UF Health Cancer Center (“UFHCC”), Integrative Medicine Department is 
conducting a research study to investigate the effects of a brief Cognitive-Behavioral Therapy 
(CBT) for sleep problems tailored for cancer patients. CBT is a form of talk therapy and is the 
recommended treatment for sleep problems, particularly insomnia.  
  
About the study: 
 This is a 4-week program delivered once a week over the telephone. 
 Before starting the program participants attend an in-person interview to further evaluate 
sleep problems and any other emotional issues. 
 Participants are randomized to participate in one of three groups: Group A receives the 
intervention via individual telephone calls, Group B receives the intervention via group 
telephone conferences, and Group C receives treatment as usual and is given the option to 
receive the intervention in a few months either in-person or by telephone.  
 Follow-up assessments are collected via telephone at 1, 3 and 6 months after end of 
program. 
 
By signing below, I acknowledge/represent the following: 
I desire to participate in the Sleeping Well study (ORMC IRB# 10.002.01). I understand that 
during my participation I will be asked about personal matters regarding my sleep patterns. It is 
possible that I may feel tired, upset or anxious. If this happens, you can choose not to answer any 
or all the questions. Additionally, a clinician is available to speak to you. I certify that I 
voluntarily applied to participate in the study and am cognizant of all of the inherent dangers and 
risks that Cognitive Behavioral Therapy for sleep problems could offer to me.  
 
My physician is signing below only to acknowledge that I am able to engage in cognitive 
behavioral therapy, and that I am able to consent to participation in the study. In the event I have 
any questions or concerns about my health before, during, or after my participation in the study, I 
am responsible to seek appropriate medical attention. 
 
As I understand my participation in the Sleeping Well study is voluntary, I agree to release 
UFHCC and anyone associated with these organizations (the “Released Parties”) from all claims 
and damages that may occur due to my participation in the study. 
 
Participant      Physician 
Signature: __________________________  Signature: __________________________ 
Print:______________________________     Print: ______________________________ 
Date: ______________________________  Date: ______________________________ 
112 
 
 
APPENDIX I: TREATMENT SATISFACTION QUESTIONNAIRE 
  
113 
 
Sleeping Well: Treatment Satisfaction Questionnaire 
 
Thank you for participating in the Sleeping Well Study. Please answer the following 
questions as honestly and accurately as possible. We appreciate your thoughtful feedback, as it 
will help us evaluate the effectiveness of Sleeping Well Program and help us make it even better 
for future participants!  
 
Next to each statement below, please put a mark (X) to show whether you “strongly 
agree”; “agree”; “disagree”; or “strongly disagree” with the statements below. 
 
 
Section 1: Your treatment Experience [Card # 47]  
 
During my contact with this treatment . . . 
Strongly 
Agree (3) 
Agree 
(2) 
Disagree 
(1) 
Strongly 
Disagree 
(0) 
 
a. The program has motivated me to work on my 
sleep problems. 
    
 
b. I did not like all the program sessions I attended. 
(reversed) 
    
 
c. I did not have enough time to talk about my own 
sleep problems. (reversed) 
    
 
d. I have not liked some of the program rules or 
regulations. (reversed) 
    
 
e. I did not find it convenient to participate in the 
program via telephone. (reversed) 
    
 
f. I felt safe and comfortable talking about my sleep 
problems. 
    
 
g. I am satisfied with the accomplishments or 
changes I have made to improve my sleep. 
    
 
h. I have learned one or more strategies to improve 
my sleep. 
    
 
i. I gained greater understanding of my sleep 
problem(s). 
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Section 2. Questions about the practitioner 
Strongly 
Agree (3) 
Agree 
(2) 
Disagree 
(1) 
Strongly 
Disagree 
(0) 
 
a. The practitioner understood my sleep 
problems and concerns. 
    
 
b. The practitioner gave me as much 
information as I wanted about what I could 
do to manage my sleep problems. 
 
    
 
c. The practitioner was good at her/his job. 
 
    
 
d. I was treated considerately and respectfully 
by the practitioner. 
 
    
 
Section 3: Overall Service Experience 
 
1. How many sessions did you complete? __________ 
 
2. Overall, how satisfied or dissatisfied are you with the Sleeping Well Program?  
 Very satisfied (4) 
 Somewhat satisfied (3) 
 Neither satisfied nor dissatisfied (2) 
 Somewhat dissatisfied (1) 
 Very dissatisfied (0) 
 
3. Overall, how helpful or unhelpful was the program manual?  
 Very helpful (4) 
 Somewhat helpful (3) 
 Neither helpful nor unhelpful (2) 
 Somewhat unhelpful (1) 
 Very helpful (0) 
 
4. Overall, how often did you practice the suggested homework or daily practice?           
 Daily (4) 
 Almost daily / Most days (4-6 days per week) (3) 
 Occasionally (1-3 days per week) (2) 
 Rarely (0-1 days per week) (1) 
 Never (0 days per week) (0) 
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5. How likely are you to suggest the Sleeping Well Program to another cancer patient?  
 Extremely likely (4) 
 Very likely (3) 
 Somewhat likely (2) 
 Not so likely (1) 
 Not at all likely (0) 
 
6. What did you find most helpful about the Sleeping Well Program? 
________________________________________________________________________ 
________________________________________________________________________ 
 
7. What did you find least helpful about the Sleeping Well Program? 
________________________________________________________________________ 
________________________________________________________________________ 
 
8. Please rate your overall experience with the Sleeping Well Program.   
 
0 1  2  3  4  5  6  7  8  9  10  
Very                    Very 
Dissatisfied                    Satisfied  
 
9. Do you have any additional comments, suggestions or concerns?  
__________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________ 
 
Section 4. Physical health and Life Changes 
 
Have you experienced any changes in your cancer treatment over the past month? 
 No   Yes; if Yes, please explain: 
____________________________________________________________________ 
 
 Have you experienced any changes in your medication over the past month? 
 No   Yes; if Yes, please explain:  
____________________________________________________________________     
 
 2a.What about Sleep medications? Any changes over the past month? 
____________________________________________________________________ 
____________________________________________________________________ 
 Have you been diagnosed with a new condition over the past month? 
 No   Yes; if Yes, please specify: 
____________________________________________________________________ 
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 Aside from participating in the Sleeping Well Program, have you participated in another 
sleep program over the past month? 
 No   Yes; if Yes, please specify: 
____________________________________________________________________ 
 
Have you experienced any major life changes over the past 2 months? 
 No   Yes; if Yes, please review the list below and let us know which event and how much 
the event has affected your life by circling the appropriate number.  
 
 Type of effect Effect of Event on Your Life 
 
Event 
Good  Bad No 
effect 
Some 
effect 
Moderate 
effect 
Great 
effect 
 Going back to work or a new job Good Bad 0 1 2 3 
 Being fired or laid off from work  Good Bad 0 1 2 3 
 Major change in your home conditions or 
living arrangements  
Good Bad 0 1 2 3 
 Separation or divorce from spouse or 
partner  
Good Bad 0 1 2 3 
 Death of a loved one Good Bad 0 1 2 3 
 Family conflicts (e.g., parenting problems, 
problems with in-laws or relatives) 
Good Bad 0 1 2 3 
 Change in your religious beliefs Good Bad 0 1 2 3 
 Loss or damage to personal property Good Bad 0 1 2 3 
 Took vacation Good Bad 0 1 2 3 
 Major change in finances (increased or 
decreased) 
Good Bad 0 1 2 3 
Other? _____________________________ Good Bad 0 1 2 3 
 
 
Thank you! Please remember that we will be in contact with you to conduct the follow-up 
assessments over the phone at 1, 3, and 6 months. 
 
 
If possible, please schedule the next telephone assessments: 
 
1 month follow-up appointment: ___________________________ 
3 month follow-up appointment: ___________________________ 
6 month follow-up appointment: ___________________________ 
End!!! 
 
Thank you for taking the time to complete these questionnaires. 
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Sleeping Well Study 
[Date]  
Dear ___________, 
Thank you for being a participant in the Sleeping Well Study! Your participation will help 
us learn whether telephone-based delivery of Cognitive-Behavioral Therapy for Insomnia is 
effective and feasible for cancer patients. We hope your experience with us has been one of 
positive learning and change. We wish you well in the unfolding moments of your life.   
 
Remember to continue practicing the strategies and skills learned throughout the Sleeping 
Well program.  Your continued healthy sleep practices will help you to improve your sleep and 
overall quality of life. If you would like to continue working on your sleep habits, we can help 
you to set up an appointment through the Integrative Medicine Department for individual and 
group therapy sessions. Furthermore, remember that you have access to many activities free of 
charge through the Cancer Support Community, including mindfulness-based stress reduction 
group, return to wellness group, yoga classes, and much more. 
 
Below are some general suggestions for continued practice: 
1. Keep a consistent sleep schedule. 
 
2. Limit daytime naps to 30 minutes. 
 
3. Avoid stimulants close to bedtime (e.g., caffeine, alcohol). 
 
4. Exercise early and regularly to promote good quality sleep. 
 
5. Stay away from food that can be disruptive right before sleep (e.g., fatty or fried meals, 
spicy dishes). 
 
6. Balance fluid intake before going to bed (i.e., enough to keep from waking up thirsty, but 
not too much that you will be awakened by the need to go to the bathroom). 
 
7. Ensure adequate exposure to natural light.  
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8. Practice a relaxing bedtime routine. 
 
9. Make sure that your sleep environment is pleasant. 
 
10. Be positive! Think about positive thoughts before going to sleep or practice gratitude by 
thinking about what you’re grateful for. 
 
Your Change Scores 
 
You completed assessments of sleep, fatigue, depression, anxiety and quality of life 
before and after the program. The table below shows the change in your scores, whether for 
better, worse or no change. We will provide you the scores for the follow-up sessions as well at 
the end of the study in about six months.  
 
    Before/Descriptor   After/Descriptor 
Insomnia Severity  _______________   _______________ 
Sleep Quality       _______________        _______________  
Sleep Efficiency    _______________    _______________ 
Depression   _______________   _______________ 
Anxiety   _______________   _______________ 
 
Thank you for your time and participation in the Sleeping Well Study. Your participation 
is valuable and very important to us. Please contact the Integrative Medicine Department for 
further questions or information.   
 
Integrative Medicine Department 
Telephone: (321)-841-5056 
Fax: (321)-843-6777 
22 W. Underwood St., 2nd Floor, MP 710-10 
Orlando, FL 32806 
UFHealthCancerOrlando.com 
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Intent to Treat Results 
 
Table 11. 
ITT Results for Demographic and Sample Characteristics by Treatment Group 
 
 
  
 TeleCBT-I 
(n = 21) 
 Control 
(n = 18) 
 
 
Variables 
Mean 
No 
SD 
% 
 Mean 
No 
SD 
% 
 
p 
Age (years) 55.05 10.15  52.28 12.32 .446 
 Range = 36 to 71  Range = 29 to 74  
Sex       .647 
     Female 19 90.5  15 83.3  
Race/Ethnicity        
     Non-Hispanic White 13 61.9  8 44.4 .142 
     African American 3 14.3  2 11.1  
     Hispanic  3 14.3  8 44.4  
     Mixed 2 9.5     
Marital status       
     Single 3 14.3  5 27.8 .444 
     Married  7 33.3  9 50  
     Divorced  8 38.1  3 16.7  
     Widowed 3 14.3  1 5.6  
Highest Level of Education       
     High School or GED - -  2 11.1 .079 
     Some College 5 23.8  6 33.4  
     Bachelor’s degree 7 33.3  8 44.4  
     Master’s degree  9 42.9  2 11.1  
Employment       
     Part-time 2 9.5  2 11.1 .509 
     Full-time 9 42.9  6 33.3  
     Unemployed 3 14.3  2 11.1  
     Retired  7 33.3  5 27.8  
     Disabled  - -  3 16.7  
Income        
     Less than $15,000 3 14.3  5 29.4 .042* 
     15,000-24,999 3 14.3  3 17.6  
     25,000-34,999 - -  4 23.5  
     35,000-49,999 4 19  - -  
     50,000-74,999 5 23.8  1 5.9  
     75,000 or more 6 28.6  4 23.5  
Note. Significance tests for continuous variables were determined with independent samples t-tests (2-
tailed), while Fisher’s exact tests were used for dichotomous and categorical variables. Income (n = 34). 
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; No, 
Frequency; %, Percentage.  
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Table 12. 
ITT Results for Cancer Related Information by Treatment Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 TeleCBT-I 
(n = 21) 
 Control 
(n = 19) 
 
 
Variables No %  No % p 
Cancer stage       
     Stage I 8 38.1  6 33.3 .327 
     Stage II 6 28.6  2 11.1  
     Stage III  3 14.3  3 16.7  
     Stage IV 3 14.3  2 11.1  
     Don’t know  1 4.8  5 27.8  
Time since cancer diagnosis      .699 
     Less than one year 7 33.3  7 38.9  
     One to two years ago 5 23.8  2 11.1  
     Two or more years ago 9 50  9 50  
Cancer location      .541 
     Breast  14 66.7  8 44.4  
     Brain  2 9.5  3 16.7  
     Skin  - -  2 11.1  
     Colon  1 4.8  1 5.6  
     Head and Neck 1 4.8  2 11.1  
     Kidney  - -  1 5.6  
     Musculoskeletal - -  1 5.6  
     Lung  1 4.8  - -  
     Blood 1 4.8  - -  
     Ovarian  1 4.08  - -  
Past cancer treatments       
     Chemotherapy 16 76.2  10 55.6 .307 
     Radiation therapy 15 71.4  11 61.1 .734 
     Surgery 15 71.4  14 77.8 .726 
     Hormone therapy 11 52.4  5 27.8 .192 
     No past treatment - -  1 5.6 .462 
Current cancer treatments          
     Chemotherapy 4 19  2 11.1 .667 
     Radiation Therapy 3 14.3  2 11.1 >.05 
     Surgery 3 14.3  3 16.7 >.05 
     Hormone therapy 7 33.3  3 16.7 .290 
    No current treatment 7 33.3  12 66.7 .056 
Note. Differences by group were determined with Chi-square and Fisher’s exact tests. 
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia;  No, 
Frequency; %, Percentage. 
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Table 13. 
ITT Results for Sleep Measures and Group Differences at Pre-treatment 
 
 
Table 14. 
ITT Results for Psychological Measures and Group Differences at Pre-treatment 
 
 TeleCBT-I 
(n = 21) 
Control 
(n = 19) 
   
Variables Mean SD Mean SD t (37) / 2 p 95% CI 
 
ISI 
 
17.76 
 
4.13 
 
17.28 
 
4.55 
 
.348 
 
.730 
 
[-2.33,  3.30] 
PSQI 12 3.23 11.94 3.93 .048 .962 [-2.27,  2.38] 
DBAS-16 5.13 1.50 5.43 1.76 -.576 .568 [-1.36,  0.76] 
Sleep Medication % (n) 52.4 11 47.6 10 .039 > .05  
 
Note. Significance tests were determined with independent samples t-tests (2-tailed) or chi-square tests. 
Abbreviations: TeleCBT-I, TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; ISI, 
insomnia severity inventory; PSQI, Pittsburgh sleep quality index; DBAS-16, dysfunctional beliefs about 
sleep.  
 
 TeleCBT-I 
(n = 21) 
Control 
(n = 18) 
   
Variables Mean SD Mean SD t (37) p 95% CI 
        
FSI  4.73 1.63 4.97 2.31 -.381 .705 [-1.53, 1.04] 
HADS-Depression 5.95 4.91 6.67 3.71 -.505 .616 [-3.58, 2.15] 
HADS-Anxiety 8.38 4.69 8.28 4.48 -.070 .945 [-2.89, 3.09] 
FACT General 69.81 19.91 71.72 15.40 -.331 .742 [-13.62, 9.79] 
     Physical  19.86 4.87 18.61 4.72 .808 .424 [-1.89, 4.37] 
     Social/Family  18.33 6.39 19.22 5.90 -.449 .656 [-4.90, 3.13] 
     Emotional  16.24 6.02 17 4.12 -.453 .653 [-4.17, 2.64] 
     Functional  15.33 6.61 16.94 4.49 -.875 .387 [-5.34, 2.12] 
QOL-CSV Total 5.66 1.63 5.53 1.35 .264 .794 [-0.85, 1.11] 
     Physical 6.34 1.62 6.27 1.71 .126 .900 [-1.02, 1.15] 
     Psychological 5.64 2.39 5.73 1.56 -.134 .894 [-1.42, 1.24] 
     Social  5.72 2.11 5.18 2.47 .729 .471 [-0.95, 2.02] 
     Spiritual  5.84 2.53 6.29 1.95 -.606 .548 [-1.93, 1.04] 
        
Note. Significance tests were determined with independent samples t-tests (2-tailed). 
Abbreviations: TeleCBT-I, TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; FSI, 
fatigue symptom inventory; HADS-D, depression subscale of hospital anxiety and depression scale; HADS-
A, anxiety subscale of hospital anxiety and depression scale; FACT, functional assessment of cancer therapy; 
QOL-CSV, quality of life patient/cancer survivor version. 
124 
 
Table 15. 
ITT Results on Sleep Measures by Each Group at Pre-treatment and Post-treatment and Treatment Effects  
 
 
 
   LMM Statistical Tests (Type III tests of fixed effects) 
  
Pre-treatment 
 
Post-treatment 
 
Time Effect 
 
Group Effect 
Group x Time 
Interaction 
 
Variables 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
F(1, 37) 
 
p 
 
F(1, 33) 
 
p 
 
g 
 
F(1, 33) 
 
p 
ISI            
   TeleCBT-I 17.76 4.13 8.52 5.23 61.26 < .001 4.61 .038 1.19 21.81 < .001 
   Control 17.28 4.55 14.94 5.54        
PSQI            
   TeleCBT-I 12 3.23 6.62 3.29 32.13 < .001 4.17 .029 1.30 21.23 < .001 
   Control 11.94 3.93 11.39 4.06        
DBAS-16            
   TeleCBT-I 5.13 1.50 3.58 1.85 20.81 < .001 2.56 .118 .72 5.81 .021 
   Control 5.43 1.76 4.95 1.95        
Note.  Between-group effect sizes were computed as Hedges’ g values. 
Abbreviations: TeleCBT-I, TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; ISI, insomnia severity 
inventory; PSQI, Pittsburgh sleep quality index; DBAS-16, dysfunctional beliefs about sleep. 
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Table 16. 
ITT Results on Psychological Measures by Group at Pre-treatment and Post-treatment and Treatment Effects  
   LMM Statistical Tests (Type III tests of fixed effects) 
  
Pre-treatment 
 
Post-treatment 
 
Time Effect 
 
Group Effect 
Group x Time 
Interaction 
Variables Mean SD Mean SD F(1, 33)  p F(1, 33) p g F(1, 33)  p 
FSI              
     TeleCBT-I 4.73 1.63 3.29 2.55 3.83  .058 3.24 .080 .88 9.95  .003 
     Control 4.97 2.31 5.31 1.98          
HADS-Depression              
      TeleCBT-I 5.95 4.91 5.76 5.94 .001  .977 .397 .533 .21 .141  .710 
     Control 6.67 3.71 6.89 4.38          
HADS-Anxiety              
      TeleCBT-I 8.38 4.69 7.14 4.01 5.83  .021 .009 .925 .03 .001  .970 
     Control 8.28 4.48 7 4.14          
FACT General              
      TeleCBT-I 69.81 19.91 77.24 23.06 .347  .560 .515 .478 .49 6.33  .016 
     Control 71.72 15.40 67.11 17.18          
Physical              
      TeleCBT-I 19.86 4.87 22.14 5.99 .002  .968 4.57 .039 .90 8.05  .007 
     Control 18.61 4.72 16.39 6.88          
Social/Family              
      TeleCBT-I 18.33 6.39 19.81 6.59 .050  .825 .043 .837 .25 1.35  .254 
     Control 19.22 5.90 18.22 5.87          
Emotional              
      TeleCBT-I 16.24 6.02 17.33 5.86 .750  .392 .007 .934 .10 1.39  .247 
     Control 17 4.12 16.83 4.15          
Functional              
      TeleCBT-I 15.33 6.61 17.95 7.46 .702  .407 .036 .850 .36 5.93  .020 
     Control 16.94 4.49 15.67 4.67          
Note. Abbreviations: TeleCBT-I, TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; FSI, fatigue symptom inventory; 
HADS-D, depression subscale of hospital anxiety and depression scale; HADS-A, anxiety subscale of hospital anxiety and depression scale; 
FACT, functional assessment of cancer therapy; QOL-CSV, quality of life patient/cancer survivor version. 
126 
 
 
Table 17. 
ITT Results on Quality of Life by Group at Pre-treatment and Posttreatment and Treatment Effects 
 
 
   LMM Statistical Tests (Type III tests of fixed effects) 
  
Pre-treatment 
 
Post-treatment 
 
Time Effect 
 
Group Effect 
Group x Time 
Interaction 
 
Variables 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
F(1,33) 
  
p 
 
F(1,33) 
 
p 
 
g 
 
F(1,33) 
  
p 
QOL-CSV Total              
      TeleCBT-I 566 1.63 5.93 1.86 .244  .624 .506 .481 .35 1.98  .167 
     Control 5.53 1.35 5.39 1.07          
Physical              
      TeleCBT-I 6.34 1.62 7.46 1.34 1.86  .180 3.56 .067 1.08 14.47  .001 
     Control 6.27 1.71 5.74 1.84          
Psychological              
      TeleCBT-I 5.64 2.39 6.17 2.33 1.49  .230 .089 .767 .23 1.56  .219 
     Control 5.73 1.56 5.72 1.28          
Social              
      TeleCBT-I 5.72 2.11 5.97 2.42 .247  .622 .916 .345 .35 .348  .559 
     Control 5.18 2.47 5.16 2.22          
Spiritual              
      TeleCBT-I 5.84 2.53 6.06 2.67 3.33  .076 .849 .363 .37 .729  .399 
     Control 6.29 1.95 6.89 1.59          
Note. Abbreviations: TeleCBT-I, Telephone-delivered Cognitive Behavioral Therapy for Insomnia, QOL-CSV, Quality of Life-Cancer Survivor 
Version. 
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